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Abstract 
 
Min Zhang 
 
THE ROLE OF SWI/SNF IN REGULATING SMOOTH MUSCLE 
DIFFERENTIATION  
 
There are many clinical diseases involving abnormal differentiation of smooth 
muscle, such as atherosclerosis, hypertension and asthma. In these diseases, 
one important pathological process is the disruption of the balance between 
differentiation and proliferation of smooth muscle cells. Serum Response Factor 
(SRF)  has been shown to be a key regulator of smooth muscle differentiation, 
proliferation and migration through its interaction with various accessory proteins. 
Myocardin Related Transcrition Factors (MRTFs) are important co-activators of 
SRF that induce smooth muscle differentiation. Elucidating the mechanism of 
how MRTFs and SRF discriminate between genes required to regulate smooth 
muscle differentiation and those regulating proliferation will be a significant step 
toward finding a cure for these diseases. We hypothesized that SWI/SNF ATP-
dependent chromatin remodeling complexes, containing Brg1 and Brm, may play 
a role in this process. Results from western blotting and quantitative reverse 
transcription - polymerase chain reaction (qRT-PCR) analysis demonstrated that 
expression of dominant negative Brg1 or knockdown of Brg1 with silence 
ribonucleic acid (siRNA) attenuated expression of SRF/MRTF dependent smooth 
muscle-specific genes in primary cultures of smooth muscle cells. 
 vi 
Immunoprecipitation assays revealed that Brg1, SRF and MRTFs form a 
complex in vivo and that Brg1 directly binds MRTFs, but not SRF, in vitro. 
Results from chromatin immunoprecipitation assays demonstrated that dominant 
negative Brg1 significantly attenuated SRF binding and the ability of MRTFs to 
increase SRF binding to the promoters of smooth muscle-specific genes, but not 
proliferation-related early response genes. The above data suggest that 
Brg1/Brm containing SWI/SNF complexes play a critical role in differentially 
regulating expression of SRF/MRTF-dependent genes through controlling the 
accessibility of SRF/MRTF to their target gene promoters. To examine the role of 
SWI/SNF in smooth muscle cells in vivo, we have generated mice harboring a 
smooth muscle-specific knockout of Brg1. Preliminary analysis of these mice 
revealed defects in gastrointestinal (GI) development, including a significantly 
shorter gut in Brg1 knockout mice. These data suggest that Brg1-containing 
SWI/SNF complexes play an important role in the development of the GI tract.  
 
 
B.Paul Herring, Ph.D, Chair 
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Chapter I: Introduction 
A. Smooth muscle development. 
During development mesenchymal stem cells differentiate into precursor smooth 
muscle cells (SMCs), characterized by the expression of smooth muscle α-actin 
in the absence of other smooth muscle-specific proteins. The precursor SMCs 
further differentiate into mature contractile SMCs characterized by their 
elongated, spindle shape and high levels of smooth muscle-specific contractile 
proteins such as smMHC, calponin, caldesmon, SM22α and telokin (57, 111). 
The origins of the mesenchymal stem cells that give rise to smooth muscle cells 
are quite diverse. In the gut, stem cells were mainly from the splanchnic 
mesoderm, which is closely surrounding the endoderm of the primitive gut tube 
(5, 146); stem cells from ventral cranial neural tube are also a source of some gut 
SMCs (11). In the vascular system, smooth muscle cells arise from a variety of 
sources. For example, stem cells from cranial neural crest give rise to the SMC 
of the aortic arch, proepicardial organ (PEO) stem cells differentiate into coronary 
artery SMCs and progenitors cells within the endothelium are a source of SMCs 
in some vessels (64).  
 
Within each smooth muscle tissue a complex cross-talk between epithelial or 
endothelial cells and smooth muscle precursor cells plays a critical role in 
organogenesis. For example, in the gut, sonic hedgehog (Shh) from the 
endoderm induces the expression of Bmp4 and Hoxd13 in the splanchnic 
mesoderm that expresses Shh receptor (Ptc) and subsequently regulate SMCs 
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differentiation (114).  Homeobox (Hox) genes are expressed in both endoderm 
and mesoderm. The expression pattern of Hox genes along the gut plays an 
important role in determining the anterior-posterior patterning of the developing 
gut (Figure 1). Evidence also shows that the mesoderm can affect endoderm 
differentiation in that small intestine mesoderm grafted onto colon endoderm 
results in the development of a small intestinal-like epithelium rather than the 
normal colonic epithelium (45).  
 
Generally there are three important determinants of SMC differentiation: 
biochemical factors, extracellular matrix (ECM) proteins and physical parameters 
(reviewed in (111), Figure 2). Besides the Shh and Hox genes discussed above, 
other biochemical factors including retinoic acid, TGFβ1, BMPs and Wnt 
signaling molecules are also important regulators of smooth muscle development 
(reviewed in (113)) (34). Heparin collagen type IV, as well as laminin in the ECM 
generally maintain SMC’s in a differentiated state and decrease proliferation 
(reviewed in (111)). Stretch and shear stress also work as mechanical factors to 
promote smooth muscle differentiation (111).  
 
B. Smooth muscle diseases. 
SMCs are very dynamic even after differentiation. In many pathological states 
contractile SMCs can transform into a proliferative, synthetic state characterized 
by decreased expression of smooth muscle-specific contractile proteins, 
increased proliferation and increased synthesis of extracellular matrix proteins 
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(reviewed in (111) (104)). For example, the expression of smooth muscle 
contractile proteins is changed during the diseases of intestinal obstruction, 
idiopathic megacolon, obstructive bladder disease, atherosclerosis, hypertension 
and asthma (3, 53) (29, 52) (78). Understanding the mechanisms by which SMCs 
regulate the transformation between differentiation and proliferation under 
physiological and pathological conditions will be an important step toward 
treating and preventing these diseases. There are many different extracellular 
signaling molecules that can affect the phenotype of smooth muscle cells under 
pathological conditions. These include cytokines such as TGFβ and peptide 
hormones such as PDGFbb and Angiotensin II (58, 64, 125, 143). These 
hormones regulate intracellular signaling cascades that affect the activity of 
transcription factors that regulate the differentiation and proliferation of smooth 
muscle cells. For example TGFβ induces the expression of smooth muscle 
contractile proteins SM22α and sm α-actin in precursor cells, while PDGFbb and 
KLF4 inhibit this induction (56). KLF4 conditional knockout mice exhibit delayed 
attenuation of smooth muscle-specific contractile protein expression following 
vascular injury (144). Our lab and other groups have shown that a zinc finger 
transcription factor, GATA6 activates expression of smMHC and sm α-actin (141) 
and is down-regulated following vascular injury (87).  Importantly, local injection 
of GATA6 into a balloon-injured carotid artery inhibited the dedifferentiation of 
SMCs and prevented lesion formation (87), demonstrating that pathological down 
regulation of important transcription activators is sufficient to alter the phenotype 
of smooth muscle cells. In a mouse model of chronic partial obstruction of the 
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small intestine, intestinal smooth muscle cells initially dedifferentiate and 
proliferate and subsequently the proliferation ceases, the cells begin to re-
differentiate and then there is hypertrophy. During this process inhibitory factors 
such as KLF4 initially increase in the proliferating SMC while the transcription 
activators such as myocardin decrease. This pattern is then reversed during the 
hypertrophic phase (29). Together these studies suggest that the dynamic 
regulation of transcription activators and repressors regulates the phenotype of 
SMC under pathological conditions. 
 
 Recent studies have also demonstrated changes in the structure of chromatin 
within smooth muscle cells under pathological conditions. Histone deacetylase 
(HDACs) activity was decreased in the lung tissue obtained from patients with 
chronic obstructive pulmonary disease (COPD)(73). Histone acetyltransferases 
(HATs) and HDACs have been shown to regulate the proliferation of SMCs which 
is involved in atherosclerosis and restenosis (108).  For example, the HDAC 
inhibitor TSA reduced vascular SMC proliferation through increasing expression 
of the cell cycle inhibitor p21 (102). In addition, deacetylation of histone H4 at the 
promoters of smooth muscle-specific genes has been associated with vascular 
injury (91). The ATP-dependent chromatin remodeling enzyme Brg1 has also 
been shown to be unregulated in vascular smooth muscle cells in primary 
atherosclerosis and in stent stenosis (148).  Together these studies suggest that 
changes in chromatin structure likely act coordinately with changes in 
transcription factor expression to regulate the phenotype of smooth muscle cells 
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under physiological and pathological conditions. 
 
C. Serum Response Factor and smooth muscle differentiation in health and 
disease. 
Serum Response Factor (SRF), is a transcription activator that has been shown 
to play a central role in smooth muscle differentiation, proliferation and migration 
through regulating the expression of muscle-specific genes, immediate early 
genes (IEGs) and cytoskeletal genes (23, 130). Smooth muscle-specific genes 
that are regulated by SRF include sm α-actin, smooth muscle myosin heavy 
chain (MHC), myosin light chain kinase (MLCK), calponin, SM22α and telokin. 
IEGs are named so because of their rapid transcriptional response to serum or 
growth factor stimulation. There are two classes of SRF-dependent IEGs: early 
IEGs (including c-fos, Egr-1, Egr-2) and late IEGs (including SRF, vinculin) 
(Figure 1). SRF activates these multiple pathways, through its association with 
distinct accessory proteins. SM-specific genes (sm α-actin, MLCK, SM22α, 
telokin) are activated by SRF-myocardin, SRF-MRTFA, SRF-GATA6-CRP2 or 
SRF-Nkx3 complexes (18, 47, 134, 141). The early IEGs are regulated by Elk 
(ets)-SRF complexes (88, 137, 151) (Figure 3). The late IEGs that are actin/Rho-
dependent are regulated by SRF-MRTFA complexes (121). SRF dimers bind the 
consensus sequence CC(A/T)6GG (CArG box) in all SRF-dependent genes 
through the MADs domain of SRF. SRF is required for mammalian development 
as SRF null embryos do not form the mesoderm from which most smooth muscle 
cells arise, and exhibit decreased c-fos, egr1 and α-actin expression (7). SRF is 
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critical for the development of all muscle lineages. Cardiac-specific SRF 
knockout mice have defects in cardiac development and less expression of sm α-
actin (101). Skeletal muscle-specific knockout of SRF in adult mice causes highly 
hypotrophic myofibers, immature muscle and low levels of skeletal α-actin (27). 
Smooth muscle-specific knockout of SRF in adult mice causes decreased 
smooth muscle contractile protein expression, resulting in decreased intestinal 
contractility and severe intestinal obstruction (4). SRF has also been reported to 
be involved in gastric ulcer and esophageal ulcer healing in rats (21, 22). SRF is 
up-regulated in epithelial, myofibroblast and smooth muscle cells in gastric ulcers 
and local injection of an SRF expression plasmid into rat gastric ulcers increased 
smooth muscle restoration and accelerated ulcer healing that was associated 
with increased expression of sm α-actin and smoothelin.  
 
Several mechanisms have been shown to regulate SRF activity (23): 
phosphorylation-dependent changes in DNA binding; alternative RNA splicing; 
regulated nuclear translocation; and association with positive and negative 
cofactors. Of these, perhaps the best studied and most important mechanism 
that regulates SRF activity is its interaction with various negative or positive 
cofactor proteins (19, 94, 134, 151) (Figure 3).  There are two major families of 
SRF cofactors: the ternary complex factor family (TCF, including Elk-1, SAP-1 
and Net) and Myocardin-Related Transcription Factor Family (MRTFs, including 
myocardin, MRTFA, MRTFB)(see the more details below and reviews by (109), 
(107)). TCFs are activated by mitogen activated protein (MAP) kinase 
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phosphorylation and regulate early response gene expression. Myocardin 
constitutively activates SRF, while MRTFA and B are regulated by a Rho-actin 
signaling pathway (see review of (109)) (Figure 3). In addition to TCFs and 
MRTFs, several other factors also associate with SRF to regulate its activity 
including positive factors such as GATA and Nkx family members and negative 
factors including FHL2 and HOP (109).  
 
D. Myocardin Related Transcription Factor Family and smooth muscle 
development. 
Identification of MRTFs as important co-activators of SRF, that potently stimulate 
expression of smooth muscle-specific genes, has been pivotal in our 
understanding of smooth muscle differentiation. This family includes Myocardin, 
Myocardin Related Transcription Factor A (MRTFA, also known as MAL or Mkl1) 
and Myocardin Related Transcription Factor B (MRTFB, also known as Mkl2). 
Myocardin, MRTFA and MRTFB share a high degree of structural homology in 
several function domains (Figure 4)(107).  An N-terminal REPEL domain is 
important for cytoskeletal actin binding; a basic and glutamine-rich region binds 
multiple factors, including SRF, SMAD1, HDAC, FOXO4; a SAP domain, named 
after SAF-A/B, Acinus, and PIAS, that may contribute to promoter binding 
specificity; a leucine zipper domain mediates dimerization of MRTFs; and a C-
terminal transcription activation domain (TAD) (107).  
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 Myocardin and MRTFA have been shown to upregulate the expression of 
smooth muscle-specific genes such as SM22α, SM-MHC, SM α-actin and telokin 
and Rho/Actin dependent genes such as SRF and vinculin, but not the MAPK/Elk 
dependent SRF target genes such as c-fos or Egr1 (30, 86, 94, 117, 143). 
MRTFA knockout mice have defects in mammary gland development: SM α-
actin, MHC, MLCK and SM22α are all significantly down regulated in mammary 
myoepithelial cells from knockout mice (mammary myoepithelial cells resemble 
SMCs and express SM-specific genes also)(80, 128). Moreover, knockdown of 
MRTFA in rat aortic SMC in vitro decreased expression of smooth muscle-
specific genes (143). Myocardin knockout mice have no vascular SMCs around 
their aorta or in the placental vasculature and die by embryonic day 10.5 (E10.5) 
due to placental vascular insufficiency (81). Neural crest-specific myocardin KO 
mice also exhibit vascular defects and die within three days of birth from patent 
ductus arteriosus associated with decreased contractile protein expression in 
smooth muscle cells of the aortic arch (67).  Similarly MRTFB KO mice die 
between E17.5 and postnatal day 1 from cardiac outflow tract defects, resulting 
from defects in the differentiation of cardiac neural crest cells into smooth muscle 
cells (79). Results from these studies demonstrate that myocardin family 
members have distinct but partially overlapping roles in regulating smooth 
muscle differentiation in vivo.  
 
Previous studies have shown that SRF has very weak or transient binding to SM-
specific gene promoters in non-muscle cells, because these promoters are in a 
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closed or condensed chromatin landscape (91). Over-expression of myocardin in 
non-muscle cells was found to open chromatin and increase SRF binding to its 
target gene promoters (91). Myocardin has also been found to increase SRF 
binding to methylated histone (91). Since no evidence shows that myocardin 
itself has chromatin remodeling functions, myocardin must recruit a chromatin 
regulator to achieve this chromatin remodeling. Also in support of this proposal 
myocardin has been shown to induce histone acetylation, at least partially 
through interacting with the histone acetyl transferases (HATs), p300 (17). 
However, it is not clear if this would be sufficient to explain how myocardin can 
open the chromatin structure of smooth muscle-specific genes to facilitate SRF 
binding. Based on data discussed below we hypothesize that Brg1/Brm ATP-
dependent chromatin remodeling enzymes may also contribute to this process. 
 
E. Brg1/Brm ATP-dependent chromatin remodeling enzymes. 
In eukaryotes, gene expression control can be achieved at several levels: 
chromatin structure, transcription, post-transcription, translation and post-
translation. The regulation of chromatin accessibility to transcription factors and 
RNA polymerase is the first level of regulation. Chromatin structure is regulated 
by 2 groups of enzymes: one group that includes HATs, histone deacetylases 
(HDACs) and histone methyltranferases catalyze covalent modification of 
histones. A second group hydrolyzes ATP to change the contacts between 
histones and genomic DNA and thereby remodel nucleosomes. The two classes 
of chromatin modifying enzymes often cooperate to remodel chromatin structure 
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through sequentially or simultaneously binding to genes to facilitate both covalent 
modification of histones and ATP-dependent remodeling of nucleosomes 
(reviewed by (40, 54, 95)). 
 
Four different classes of ATP-dependent chromatin remodeling complexes have 
been found and named after their unique ATPase subunits: SWI/SNF, ISWI, Mi-2 
and Ino80. SWI/SNF is the most characterized complex in mammalian cells. 
Brg1 (Brahma related gene one) and Brm (Brahma) are the ATPase subunits of 
the SWI/SNF complex. The SWI/SNF remodeling complex has been shown to 
play an essential role in the differentiation of many tissues, including the neural 
system, T cells, liver, skeletal and cardiac muscle (46, 66, 89). A dominant 
negative Brg1 has been shown to block MyoD-mediated induction of skeletal 
muscle-specific genes (38) and Baf60c (a component of the SWI/SNF complex) 
is required for heart development. During skeletal muscle differentiation, the 
dominant transcription factor MyoD initially binds weakly to the myogenin 
promoter through its interaction with Pbx. MyoD then recruits SWI/SNF and 
SWI/SNF remodels the structure of the myogenic locus facilitating tight binding of 
MyoD to E boxes within the myogenin promoter, subsequently activating 
myogenin expression and skeletal muscle differentiation (38). The recruitment of 
SWI/SNF by MyoD is thus critical for skeletal muscle differentiation. MRTFs in 
smooth muscle cells are somewhat analogous to the MyoD family in skeletal 
muscle cells. Given this analogy and the requirement of MRTFs to recruit 
chromatin remodeling enzymes to facilitate SRF binding during smooth muscle 
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differentiation we thus proposed that MRTFs may recruit SWI/SNF to facilitate 
this process. This proposal leads me to develop the following hypothesis, which 
is the foundation for my research studies:  
 
F. Hypothesis 
SWI/SNF ATP-dependent chromatin remodeling enzymes containing either Brg1 
or Brm as their catalytic subunits, play a critical role in the activation of SRF-
dependent genes by MRTFs during smooth muscle development.  
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Figure 1.  The gradient expression of transcription factors in GI tract 
development. (Adapted from Yuasa, et al, 2003 Nat Rev Cancer).  
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Figure 2. Three important determinants of SMC differentiation and 
phenotypic changes. 1). Biochemical factors: Retinoids, TGF-β, PDFGB et al. 
2). Extracellular matrix (ECM proteins): Heparin, collagen, laminin, and 
fibronectin. 3). Physical parameters: stretch, shear stress. (Adapted from Rensen 
et al, 2007 Neth Heart J.) 
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Figure 3. SRF/MRTFs target genes. (Adapted from Cen et al, 2003 J.Cell. 
Biochem) 
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Figure 4. The structural domains and binding partners of the MRTF family. 
A. Structural domains of Myocardin, MRTFA and MRTFB. The similarity 
percentage between each domain relative to myocardin is shown. B. Binding 
partners of MRTF family. REPEL domain, basic and glutamine-rich region, SAP 
domain, Leucine zipper domain, transcription activation domain (TAD). (Adapted 
from G. C. Pipes et al, Genes Dev, 2006) 
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Chapter II: A novel role of Brg1 in the regulation of SRF/MRTFA-dependent                      
smooth muscle-specific gene expression 
Abstract 
Serum Response Factor (SRF) is a key regulator of smooth muscle 
differentiation, proliferation and migration. Myocardin Related Transcription 
Factor A (MRTFA) is a co-activator of SRF that can induce expression of SRF-
dependent, smooth muscle-specific genes and actin/Rho-dependent genes, but 
not MAPK regulated growth response genes. How MRTFA and SRF discriminate 
between these sets of target genes is still unclear. We hypothesized that 
SWI/SNF ATP-dependent chromatin remodeling complexes, containing Brahma-
related gene 1 (Brg1) and Brahma (Brm), may play a role in this process. Results 
from western blotting and qRT-PCR analysis demonstrated that dominant 
negative Brg1 blocked the ability of MRTFA to induce the expression of smooth 
muscle-specific genes, but not actin/Rho-dependent early response genes in 
fibroblasts. In addition, dominant negative Brg1 attenuated expression of smooth 
muscle-specific genes in primary cultures of smooth muscle cells. MRTFA over-
expression did not induce expression of smooth muscle-specific genes in SW13 
cells, which lack endogenous Brg1 or Brm. Reintroduction of Brg1 or Brm into 
SW13 cells restored their responsiveness to MRTFA. Immunoprecipitation 
assays revealed that Brg1, SRF and MRTFA form a complex in vivo and Brg1 
directly binds MRTFA, but not SRF, in vitro. Results from chromatin 
immunoprecipitation assays demonstrated that dominant negative Brg1 
significantly attenuated the ability of MRTFA to increase SRF binding to the 
 17 
promoters of smooth muscle-specific genes, but not early response genes. 
Together these data suggest that Brg1/Brm containing SWI/SNF complexes play 
a critical role in regulating expression of SRF/MRTFA-dependent smooth muscle-
specific genes but are not required for SRF/MRTFA-dependent early response 
genes.  
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Introduction 
 
There are many diseases, such as atherosclerosis, hypertension and asthma 
that involve abnormal differentiation of smooth muscle cells. An important 
pathological process that occurs in these diseases is the disruption of the 
balance between differentiation and proliferation of smooth muscle cells (53, 104, 
120, 140). Serum Response Factor (SRF) has been shown to play an essential 
role in regulating smooth muscle differentiation, proliferation and migration 
through its interaction with various accessory proteins (93). Smooth muscle-
specific genes, such as SM α-actin, SM MHC, 130kDa MLCK, SM22α, and 
telokin, are activated by SRF-myocardin, SRF/MRTFA, SRF/GATA6/CRP2 or 
SRF/Nkx complexes (19, 26, 30, 43, 44, 82, 100, 106, 107, 138, 142, 143, 145, 
151). The immediate early growth factor responsive genes, such as c-fos and 
Egr-1 are regulated by SRF/Elk (ets) complexes (88, 110, 119). The later early 
response genes, such as SRF itself and vinculin, that are actin/Rho-dependent, 
are regulated by SRF/MRTFA complexes (19, 94, 121). Myocardin Related 
Transcription Factor A (MRTFA, or Mkl1, MAL, BSAC) is a unique co-activator of 
SRF in that it is involved in the regulation of multiple SRF-dependent gene 
families (reviewed by (20)). MRTFA has been reported to induce SRF-
dependent, smooth muscle-specific genes such as telokin, SM22α and SM α-
actin and actin/Rho-dependent early response genes, but not proliferation related 
MAPK-dependent immediate early response genes (19, 43, 121, 143). It still 
remains a mystery how MRTFA can discriminate between different SRF-
dependent genes. One possible mechanism could involve gene-specific 
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restriction of promoter access due to chromatin structure. In support of this 
model, it has been shown that there is very little SRF detectable at the CArG 
boxes of smooth muscle-specific genes in nonmuscle cells, whereas SRF 
binding can be readily detected at CArG boxes of early response genes such as 
c-fos (91). In addition, over-expression of myocardin in nonmuscle cells was 
found to lead to increased SRF binding to the promoters of smooth muscle-
specific genes. In the current study we provide evidence supporting a role for 
ATP-dependent chromatin remodeling in regulating SRF binding to CArG boxes 
within promoters of smooth muscle-specific genes. 
 
Since chromatin is highly condensed, the regulation of chromatin accessibility to 
transcription factors and RNA polymerase is an essential step in gene activation 
(40, 131). Although studies have shown that myocardin can recruit enzymes 
capable of modifying chromatin structure through covalent modification of histone 
tails (17, 35), no studies have examined how chromatin structure affects 
promoter access by MRTFA. In addition, the role of ATP-dependent chromatin 
remodeling enzymes in the regulation of smooth muscle differentiation is 
unknown. The SWI/SNF complex is the best characterized, mammalian, ATP-
dependent chromatin remodeling complex (40). It is comprised of 7 to 11 
components, which assemble into distinct complexes containing either Brg1 
(Brahma-related gene 1) or Brm (Brahma) ATPase subunits. SWI/SNF 
remodeling complexes have been shown to play an essential role in the 
differentiation of neurons, T cells, erythrocytes, hepatocytes, adipocytes, skeletal 
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and cardiac muscle cells (16, 31, 32, 37, 69, 70, 105, 116, 122, 132, 133). 
Although, the role of Brg1 or SWI/SNF in smooth muscle development is largely 
unknown, Brg1 has been shown to be upregulated in vascular smooth muscle 
cells in primary atherosclerosis and in stent stenosis (148). A recent study has 
also demonstrated that Brg1 binding to CRP2 is critical for induction of smooth 
muscle-specific genes by CRP2 (24). During skeletal muscle differentiation it has 
been shown that the recruitment of Brg1 to MyoD, that is associated with DNA 
bound Pbx1, induces chromatin remodeling of the myogenin gene. This 
facilitates tight binding of MyoD to E boxes resulting in co-factor recruitment and 
transcription activation (38). By analogy, we propose that weak SRF binding to 
the CArG boxes of smooth muscle-specific genes may facilitate recruitment of 
MRTFA and that interaction of MRTFA with SWI/SNF may then remodel 
chromatin permitting tight binding of SRF.  
 
Results from our study demonstrate that Brg1 is required for the induction of 
smooth muscle-specific gene expression but not for early response gene 
expression by MRTFA. Endogenous Brg1, SRF and MRTFA were found to form 
a complex in smooth muscle cells and tissue and Brg1 directly bound to MRTFA, 
but not SRF, in vitro. Chromatin immunoprecipitation assays revealed that 
SWI/SNF is required for MRTFA to increase SRF binding to the promoters of 
smooth muscle specific genes. Furthermore, expression of a dominant negative 
Brg1 in differentiated smooth muscle cells attenuated expression of smooth 
muscle specific genes. Together these data indicate that SWI/SNF plays a critical 
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role in regulating expression of SRF/MRTFA-dependent smooth muscle-specific 
genes but not SRF-dependent early response genes. SWI/SNF thus plays an 
important role in regulating the balance between the differentiation and 
proliferation roles of SRF. 
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Experimental Procedures 
Cell culture and adenoviral transduction. An MRTFA cDNA image clone was 
purchased from Invitrogen (Clone ID: 682130) and moved to Adeno-X vector 
according to the manufacturer’s protocol (BD Biosciences). Adenovirus encoding 
nuclear localized YFP (Yellow Fluorescent Protein) was used as negative control. 
B22 cells, which are NIH3T3 cells that express a tetracycline inducible dominant 
negative Brg1 (DN-Brg1, K798R mutant) (36), were obtained from Dr. Anthony N. 
Imbalzano (University of Massachusetts Medical School, Worcester, 
Massachusetts). By withdrawing tetracycline from the growth media of these 
cells, the expression of DN-Brg1 can be induced. B22 cells were maintained in 
high glucose Dulbecco’s modified Eagle’s medium (DMEM) (Mediatech) 
containing 2 µg/ml tetracycline, 350 units/ml Hygromycin B, 75 µg/ml G418 and 
10% fetal bovine serum (FBS). B22 cells were seeded into 6 well dishes at the 
density of 2×105cells per well in the medium either with or without tetracycline 
and grown for 24 hours prior to adenoviral transduction. Cells were incubated 
with adenovirus encoding MRTFA or YFP for 4 hrs at 37°C and then replaced 
with complete medium. 30-48 hrs after transduction, cells were harvested for 
protein, RNA or chromatin Immunoprecipitation analysis. SW13 and HeLa cells 
were obtained from ATCC and grown in high glucose DMEM containing 5 
units/ml penicillin, 50 mg/ml streptomycin and 10% FBS. 24 hours before 
transduction, SW13 and HeLa cells were seeded at the density of 2.5 ×105 cells 
per well in 6 well dish. Cells were then transduced with adenovirus as described 
above for B22 cells. Primary mouse colon smooth muscle cells were prepared 
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from colons dissected from 4-week-old mice. The epithelial layer was removed 
and remaining smooth muscle layer was minced and digested with 1ml of tissue 
digestion buffer per organ ((0.4 units/ml Blendzyme #3 (Roche) in DMEM) at 
37°C for 1-2 hours with shaking. The digested tissue is then passed through a 
cell sieve and the cells collected by centrifugation. Pelleted cells are washed in 
DMEM containing 10% FCS and penicillin/streptomycin and plated into dishes. 
After 4-5 days cells reached confluence, were trypsinized and replated at 7x104 
per well in 12 well plates. 12 hours after plating cells were transduced by DN-
Brg1 or YFP control adenovirus. 72 hours after transduction, mRNA was 
harvested and the levels of SRF dependent genes were measured by 
quantitative real time RT-PCR.  
 
Plasmids used and cell transfection. Human Brg1 and Brm cDNA and DN-
Brg1 in pBABE retroviral expression plasmids were obtained from AddGene 
(124). MRTFA was cloned into pcDNA myc His (Invitrogen) for transfection and 
in vitro translation experiments. HA-SRF pShuttle was generated by cloning the 
human SRF cDNA into a modified pShuttle (Clontech) vector that includes an 
amino-terminal HA epitope tag. 12 hrs prior to transfection, cells were seeded at 
the density of 2.5×105 cells per well in 6 well plates. Plasmids were transfected 
into cells using Fugene 6 (Roche Applied Science): cells were washed once with 
phosphate-buffered saline (PBS) (pH 7.4) then 2 ml of complete medium was 
added to each well together with 2 µg plasmid DNA and 4 µl Fugene in 100 µl 
DMEM.  
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RNA analysis. RNA was extracted with Trizol reagent (Invitrogen). 1.2 µg RNA 
was used as template for reverse transcription (RT) using Superscript first strand 
cDNA synthesis kit (Invitrogen). cDNA was dissolved in 20 µl H2O. The cDNA 
levels of specific genes were measured by quantitative real time PCR using 
SYBR green PCR master mix (Invitrogen) and a 7500 Real Time PCR system 
(Applied Biosystems) with gene specific primers (Table 1). 2 µl of 1:10 diluted 
cDNA was used to each reaction in 25 µl total volume. All PCR reactions were 
performed in duplicate.  
 
Western blotting. Protein was extracted with RIPA lysis buffer. Protein 
concentrations were determined by using a BCA Protein Assay Kit (Pierce). 30 
µg of proteins were fractionated on 7.5 or 15% SDS-polyacrylamide gels and 
transferred to nitrocellulose or polyvinyl difluoride membranes.  Membranes were 
then probed with a series of antibodies. Antibodies used for western blotting were 
against: Brg1 (Upstate, 1:5,000), Brm (Abcam, 1:1000) MRTFA (Santa Cruz, C-
19, 1:500), SRF (Santa Cruz, G20X, 1:6,000), α-actin (Sigma, 1:10,000), Egr-1 
(Santa Cruz, 1:1,000), Flag tag (Sigma, M2, 1:5,000), HA tag (Covance, 
1:3,000), myc tag (Invitrogen, 1:1000), MLCK (Sigma, clone K36, 1:10,000), SM 
 α-actin (Sigma, clone 3A1, 1:10,000), SM22α (a gift from Dr. Len Adam, 
1:6,000), telokin (1:6,000) (50), vinculin (Santa Cruz, 1:5,000), NMMHC IIA (a gift 
from Dr. Patricia Gallagher). Primary antibodies were detected using horseradish 
peroxidase conjugated secondary antibodies and visualized using 
chemiluminescence.  
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Co-immunoprecipitation (Co-IP).  Co-IP assays were performed using a 
nuclear complex Co-IP kit, essentially as described by the manufacturer (Active 
Motif). 250 µg of nuclear protein extracts were incubated with 3 µg of anti-Brg1 
antibody (Upstate), anti-SRF antibody (Santa Cruz, G20X), anti-MRTFA antibody 
(Santa Cruz, C-19; or ProteinTech), or appropriate IgG control in 500 µl of low 
salt IP buffer (Active Motif) overnight at 4°C. 60 µl of EZview protein A beads 
(Sigma) were added to the mixture and incubated for an additional hour with 
rocking. Beads were then washed 6 times with the low salt IP buffer. The 
immunoprecipitated proteins were dissolved in 35 µl of 2XSDS sample buffer and 
boiled for 5 minutes, prior to analysis by western blotting as described as above.  
 
In vitro transcription/translation. Synthesis of proteins was carried out in a 
coupled transcription/translation system (Promega, Madison, WI) in vitro, 
programmed with 1µg of pShuttle-Brg1 (flag tag), pcDNAmyc/his-MRTFA (myc 
tag) and pShuttle-SRF (HA tag) plasmids. The TNT products were mixed 
together as combinations of: SRF with Brg1, MRTFA with Brg1, SRF with 
MRTFA, in 250 µl low salt IP buffer (Active Motif). Proteins were 
immunoprecipitated with 3 µg anti-SRF (Santa Cruz, G20X) or 15µl anti-MRTFA 
antiserum over night. A matching rabbit IgG or a MRTFA preimmune serum 
served as negative controls. The immunoprecipitated proteins were then 
incubated with EZ-view beads (Sigma) for 2 hours. Following 6 washes with IP 
buffer the beads were dissolved in SDS-sample buffer and subjected to Western 
blotting as described above. 
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Quantitive chromatin immunoprecipitation (ChIP) assays. ChIP assays were 
performed according to the protocol of Upstate with minor modifications. Cells 
were fixed in 3.7% formaldehyde for 15 minutes at room temperature and 
harvested using cold PBS with protease inhibitors. After collecting cells by 
centrifugation, cell pellets were lysed using 1%SDS lysis buffer (200 µl / 1×106 
cells). For each group, 1ml of lysate was sonicated for 7 x30 seconds at setting 
2.25 on a Sonic Dismembranator (Fisher Scientific). 200 µl aliquots of chromatin 
were immunoprecipitated using 6µg of anti-SRF antibody (Santa Cruz, G20X), 
anti-H3Ac (Upstate) or rabbit IgG as negative control. The precipitated genomic 
DNA was purified and the presence of specific promoters was measured by real 
time quantitative PCR, using gene specific primers (Table 2).  
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Results 
DN-Brg1 inhibits the ability of MRTFA to induce expression of smooth 
muscle specific genes, but not SRF-dependent early response genes. To 
determine the role of SWI/SNF mediated chromatin remodeling on the induction 
of genes by SRF/MRTFA, we utilized a previously characterized 3T3 cell line that 
inducibly expresses a dominant negative Brg1 (B22 cells, (36)). The dominant 
negative K798R mutant Brg1 blocks the function of SWI/SNF complexes 
containing Brg1 or Brm catalytic subunits. B22 cells were transduced with 
MRTFA or YFP adenovirus. 30 hours after transduction, cells were lysed and 
mRNA and protein expression analyzed by quantitative real-time RT-PCR and 
western blotting, respectively (Figures 5, 6). In agreement with previous reports 
(43, 82, 121, 135, 143) MRTFA induced the expression of several smooth 
muscle-specific genes in fibroblast cells (Figure 5, compare solid bars to open 
bars in control cells). In contrast, MRTFA did not significantly induce expression 
of the early response genes, c-fos, Egr-1 or vinculin, although it did result in a 2-
fold increase in expression of SRF mRNA (Figure 6).  As shown by western 
blotting (Figure 6) and more quantitatively by qRT-PCR (Figure 5) dominant 
negative Brg-1 significantly abrogated the ability of MRTFA to increase 
expression of telokin, SM22α, and calponin but not SM α-actin or any of the 
SRF-dependent early response genes examined. Conversely, DN-Brg1 
augmented the ability of MRTFA to increase SRF mRNA expression and 
increased the basal expression of Egr-1 and c-fos mRNA (Figure 5). 
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MRTFA cannot induce smooth muscle-specific genes in SW13 cells that 
lack Brg1 and Brm.  It is possible that DN-Brg1 inhibits the activity of more than 
just Brg1 and Brm containing SWI/SNF complexes, hence we also examined the 
role of Brg1 in a Brg1/Brm null cell system. The ability of MRTFA to induce gene 
expression in human adrenal carcinoma SW13 cells that lack endogenous 
Brg1/Brm was determined. Human cervical cancer HeLa cells that express Brg1 
and Brm were used as control for these experiments. Results from western blot 
analysis showed that over-expression of MRTFA in SW13 cells could not induce 
the expression of most smooth muscle-specific genes, including 130kDa 
smMLCK, telokin, or SM22α, and could only weakly induce sm α-actin 
expression (Figure 7A). In contrast, MRTFA readily induced expression of these 
genes in HeLa cells. MRTFA induced expression of SRF and vinculin in SW13 
cells as well as in HeLa cells. Although Egr-1 was not induced by MRTFA in 
either of these two cell types, the basal expression of Egr-1 appeared higher in 
SW13 cells compared with HeLa cells. Surprisingly, MRTFA was able to induce 
expression of c-fos in SW13 cells but not in HeLa cells (Figure 7A) and this 
induction was attenuated by reintroduction of Brg1 into the SW13 cells (Figure 
7B). These results are consistent with the results obtained from the DN-Brg1 3T3 
cell lines.  To verify that the inability of MRTFA to induce smooth muscle-specific 
genes in SW13 cells is due to the lack of Brg1/Brm, we reintroduced Brg1 or 
Brm1 back into SW13 cells. Western blot analysis demonstrated that restoration 
of Brg1 or Brm expression could rescue the ability of MRTFA to induce the 
expression of smooth muscle-specific proteins in SW13 cells (Figure 7B).  
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DN-Brg1 attenuates smooth muscle gene expression in primary smooth 
muscle cells. The above results suggest that Brg1 or Brm is required for MRTFA 
to induce the expression of smooth muscle specific genes in non-smooth muscle 
cells.  To determine if Brg1 is required for smooth muscle cells to maintain the 
expression of smooth muscle-specific markers, DN-Brg1 was over expressed in 
primary colon smooth muscle cells. Results from quantitative real-time RT-PCR 
demonstrated that dominant negative Brg-1 significantly decreased the 
expression of smooth muscle specific genes (telokin, SM MHC, calponin, SM22α 
and sm α-actin) and increased the expression of the SRF-dependent early 
response genes, such as egr1 and c-fos. The expression of SRF was not 
significantly changed (Figure 8).  
 
Brg1 interacts with SRF and MRTFA in intact cells. We next determined if 
Brg1 could interact with MRTFA and/or SRF in intact cells. Co-
immunoprecipitation (Co-IP) assays were performed from COS cells transduced 
with HA- tagged MRTFA and SRF adenoviruses. MRTFA, SRF and endogenous 
Brg1 were immunoprecipitated from the transduced cell extracts. Western 
blotting of immunoprecipitated proteins showed that MRTFA immunoprecipitates 
contained Brg1, MRTFA and SRF (Figure 9A). SRF immunoprecipitates 
contained MRTFA and SRF, and a very weak Brg1 signal. Similarly Brg1 
immunoprecipitates contained Brg1 and MRTFA and a small amount of SRF. 
These data indicate that Brg1, MRTFA and SRF can form a complex in vivo. To 
confirm this finding, we determined if the endogenous proteins can also be 
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detected in a complex in A10 smooth muscle cells (Figure 9B) or in bladder 
tissue (Figure 9C). Endogenous Brg1, SRF and MRTFA were 
immunoprecipitated from nuclear extracts of A10 cells or mouse bladder and 
western blot analysis revealed that Brg1 can be co-immunoprecipitated with SRF 
and MRTFA. These data indicate that the 3 proteins can form a complex in A10 
smooth muscle cells and bladder tissue in vivo (Figure 9B,C). 
 
Brg1 interacts with MRTFA but not SRF in vitro. To determine if Brg1 directly 
binds to MRTFA and/or SRF, in vitro binding assays were performed. Brg1, 
MRTFA and SRF were synthesized in vitro using a coupled in vitro transcription 
and translation system. pShuttle-Brg1 (Flag tag), pcDNA myc/his-MRTFA (myc 
tag) and pShuttle-SRF (HA tag) were utilized as templates for the 
transcription/translation reactions. In vitro synthesized proteins were incubated 
together and immunoprecipitation assays were used to identify the interacting 
proteins (Figure 10). Results from this analysis indicate that Brg1 could be co-
precipitated with MRTFA but not with SRF, demonstrating that Brg1 can directly 
bind to MRTFA.  
 
DN-Brg1 inhibits the ability of MRTFA to increase SRF binding to the 
promoters of smooth muscle-specific genes. To explore why Brg1 is required 
for MRTFA induced smooth muscle-specific gene expression, but not for 
expression of the early response genes, chromatin immunoprecipitation (ChIP) 
assays were performed. B22 cells were grown in the presence or absence of 
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tetracycline and transduced with adenovirus encoding MRTFA or YFP. ChIP 
assays were performed to examine SRF binding to SRF-dependent promoters as 
described in ‘ Experimental Procedures ’. Consistent with previous studies using 
myocardin (91), we found that MRTFA significantly increased SRF binding to the 
promoters of smooth muscle-specific genes, telokin, SM22α and SM α-actin, 
(Figure 11A). DN-Brg1 dramatically attenuated the ability of MRTFA to increase 
SRF binding to the telokin and SM22α promoters, but not the SM α-actin 
promoter (Figure 11B). In contrast, neither MRTFA nor DN-Brg1 affected the 
SRF binding to the promoters of the early response genes, SRF and c-fos 
(Figure 11A, B). In addition to increasing SRF binding to the telokin promoter, 
MRTFA also increased levels of acetylated histone H3 (Figure 11A, right panel). 
This increase in acetylated histone H3 on the telokin promoter was blocked by 
expression of DN-Brg1. In contrast, the small increase in acetylated H3 on the 
SM α-actin promoter was not blocked by DN-Brg1 (Figure 11B, right panel). 
Under control conditions (no DN-Brg1 expression), in YFP transduced B22 cells, 
there appeared to be more SRF bound to the SM α-actin, SRF, and cfos 
promoters as compared to the telokin and SM22α promoters (Figure 11C, left 
panel). Similarly there was more acetylated histone H3 associated with the SM α-
actin promoter as compared to the telokin promoter under control conditions 
(Figure 11C, right panel). 
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Discussion 
In this study, we found that Brg1 or Brm are required for the MRTFA-mediated 
induction of smooth muscle-specific genes, but not early response genes. DN-
Brg1 attenuated the induction of smooth muscle-specific genes and reintroducing 
Brg1/Brm into SW13 cells restored their responsiveness to MRTFA. Brg1 
appears to be required for MRTFA to increase the binding of SRF to the 
promoters of smooth muscle-specific genes, within intact chromatin.  Brg1, 
MRTFA and SRF were found to form a complex in smooth muscle cells in vivo 
and Brg1 directly bound MRTFA but not SRF in vitro. Since previous studies (19, 
94, 135), and data presented in Figure 6 have shown that MRTFA directly binds 
SRF in vitro, MRTFA can thus act as a bridge to connect Brg1 and SRF.  
 
Results shown in Figures 5 and 6 demonstrate that DN-Brg1 blocked the 
MRTFA-mediated induction of telokin, SM22α and calponin but did not 
significantly block the induction of SM α-actin. However, from results shown in 
Figure 5 it is apparent that SM α-actin, but not other smooth muscle marker 
genes, was readily detectable in B22 3T3 cells prior to over-expression of 
MRTFA (YFP control group). This indicates that the SM α-actin locus is 
transcriptionally active in control cells and thus likely to be in an open chromatin 
conformation in these cells. In support of this hypothesis, there was significantly 
more SRF and acetylated histone H3 associated with the SM α-actin promoter as 
compared to the telokin promoter in control cells (Figure 11C). Thus it might be 
predicted that Brg1 containing SWI/SNF complexes may not be required to 
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further open the chromatin structure of the SM α-actin promoter in order for 
MRTFA to increase SRF binding to the promoter. This suggests a model in which 
Brg1 is required for MRTFA to increase binding of SRF to the promoters of 
transcriptionally silent genes but not to genes that are already transcriptionally 
active within native chromatin (Figure 12).  
 
As the MRTFA regulated early response genes are also expressed in control 
cells, our model would predict that activation of these genes would also be 
independent of Brg1. This is consistent with data presented in Figure 1 showing 
that MRTFA-mediated induction of SRF was not inhibited by DN-Brg1. In 
addition, under control conditions there was markedly more SRF bound to the 
SRF promoter as compared to the telokin or SM22α promoters (Figure 11C). In 
our experiments only in SW13 cells did we detect any activation of vinculin by 
MRTFA (Figure 7A), although this activation was not altered by expression of 
Brg1 or Brm (Figure 7B), suggesting that it is independent of these proteins. In 
agreement with previous studies (121) we also observed no affects of MRTFA on 
expression of MAPK dependent SRF-target genes such as c-fos or egr1 (Figure 
5). However, the basal expression of c-fos and Egr-1 is higher in cells expressing 
DN-Brg1  (Figure 5) and in cells lacking Brg1/Brm (SW13 cells compared to 
HeLa cells in Figure 7A). This observation is consistent with a previous study that 
showed that Brg1 represses c-fos expression (98). It is not known why Brg1 
inhibits c-fos expression, though it might be predicted that it either results in 
increased binding of a repressor or it may alter the positioning of the 
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nucleosome, which has been shown to be located between key regulatory 
elements in the c-fos promoter (118). As Brg1 is specifically required for MRTFA 
to induce expression of smooth muscle-specific genes but not early response 
genes, then regulation of MRTFA/Brg1 interactions could provide a mechanism 
for a cell to switch between activation of these two groups of genes.  
 
Previous studies showed that Brg1 knockout mice die during the periimplantation 
stage (15), however, Brm knockout mice develop normally, except that adult 
mice have higher body weight (112). These data suggest that Brg1 has non-
redundant functions that cannot be replaced by Brm. However, in our 
experiments we found that either Brg1 or Brm were required for MRTFA to 
induce expression of smooth muscle-specific genes. This is in contrast to a 
recent study that demonstrated that Brg1 but not Brm is required for CRP-
mediated induction of smooth muscle-specific genes in cardiac myocytes (24). 
Future analysis of smooth muscle-specific knockouts of Brg1 will be required to 
determine the specific role of Brg1 and Brm in smooth muscle cells in vivo.  
 
Although Brg1 is ubiquitously expressed, Brg1 has been shown to selectively 
rather than broadly regulate gene expression (39). This can be explained, at 
least in part, by the recruitment of Brg1 to individual promoters through its 
interaction with specific transcription factors (6, 8, 9, 14, 24, 38, 49, 105, 115). 
Our results further support this idea as we found that Brg1, SRF and MRTFA 
form a complex in smooth muscle tissue in vivo and Brg1 directly interacts with 
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MRTFA but not SRF (Figure 10). This would allow Brg1 to be recruited to 
MRTFA-dependent SRF target genes but not to Elk-dependent SRF target 
genes. A recent study has also shown that CRP2 directly binds to Brg1 (24), and 
CRP2 has previously been shown to form a complex with SRF in some smooth 
muscle cell types (25). Thus, CRP2 may act similar to MRTFA to facilitate 
recruitment of Brg1 complexes to mediate stable SRF binding to the promoters of 
smooth muscle-specific genes.  
 
It is likely that the ATP-dependent chromatin remodeling catalyzed by Brg1/Brm 
acts together with covalent histone modifications to permit stable SRF/MRTFA 
binding and transcription activation. Although SWI/SNF itself does not covalently 
modify histones its’ remodeling of chromatin through nucleosome reorganization 
can facilitate the recruitment of other proteins that covalently modify histones. 
Previous studies have shown that over-expression of Myocardin, an MRTFA 
homologue, can induce histone acetylation through myocardin’s interaction with 
the HAT, p300 (17). Histone acetylation has also been shown to promote the 
binding of SWI/SNF complexes to chromatin, as the acetylated histone tail can 
bind to the bromodomain of Brg1 (2). Thus MRTFA/p300 induced histone 
acetylation, may further stabilize Brg1 binding to the promoters of smooth 
muscle-specific genes (Figure 12). In a reciprocal fashion Brg1-induced changes 
in chromatin structure will facilitate increased binding of SRF/MRTFA complexes 
to the promoter and thus result in increased recruitment of p300. Together these 
interactions can then lead to transcription activation.  
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In summary, we propose a model in which the recruitment of MRTFA/Brg1 
complexes to weakly bound SRF at the promoters of smooth muscle-specific 
genes, leads to chromatin remodeling which facilitates tight binding of SRF 
complexes and subsequent transcription activation (Figure 12, upper panels). In 
contrast, in cells grown under high serum conditions, SRF is tightly bound to the 
promoters of SRF-dependent early response genes. Brg1 is thus not required to 
permit MRTFA or MAPK-Elk signals to activate these genes (Figure 12, lower 
panels). 
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Figure 5. The expression of DN-Brg1 in 3T3 fibroblasts interferes with the 
induction of endogenous SRF-dependent smooth muscle-specific genes by 
MRTFA. Inducible DN-Brg1 3T3 (B22) cells were plated in media either with or 
without tetracycline. 24 hours later, cells were transduced with MRTFA (solid 
bars) or YFP (open bars) adenovirus. 30-48 hours following transduction cells 
were lysed for mRNA analysis. mRNA was isolated from cells and the levels of 
mRNA expression were measured by quantitative real time RT-PCR. Transcript 
levels was firstly normalized to acidic ribosomal phosphoprotein PO (RPLPO) 
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internal loading control and then normalized to their respective YFP control 
group. The ΔΔCt method was used to calculate the relative quantity values (RQ) 
of gene expression levels. Ct is the threshold cycle where the amplification of 
template begins. RQ=2-ΔΔCt and ΔΔCt = (Ct experimental-Ct RPLPO)- (Ct control-Ct RPLPO).  
Data presented are the mean±SEM of 8-9 samples obtained from 3 independent 
experiments. * Indicates statistical significance as determined by a student T test 
(P<0.05).  
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Figure 6. The expression of DN-Brg1 in 3T3 fibroblasts interferes with the 
induction of endogenous SRF-dependent smooth muscle-specific proteins 
by MRTFA. Inducible DN-Brg1 3T3 (B22) cells were plated in media either with 
or without tetracycline. 24 hours later, cells were transduced with MRTFA or YFP 
adenovirus. 30-48 hours following transduction cells were lysed using RIPA lysis 
buffer and protein expression analyzed by western blotting. 30 µg of protein were 
loaded in each lane.  
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Figure 7. MRTFA cannot induce smooth muscle-specific gene expression 
in SW13 cells that lack Brg1/Brm1. A. SW13 and HeLa cells were transduced 
with MRTFA or YFP adenovirus, 48 hrs later, protein extracts were prepared and 
analyzed by western blotting. 30µg of protein were loaded onto each lane. * The 
upper band seen on the c-fos blots is a non-specific signal. β-actin was used as a 
loading control. B. WT-Brg1 or Brm-pBabe expression plasmids or empty vector 
control plasmids were transfected into SW13 cells in duplicate. After 24 hrs, cells 
were transduced with MRTFA adenovirus (low amount +, higher amount ++). 48 
hours later cells were lysed by RIPA lysis buffer and analyzed by western 
blotting. NM-MHC2A serves as a loading control. 
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Figure 8. DN-Brg1 interferes with smooth muscle gene expression in 
primary smooth muscle cells. Primary colon smooth muscle cells were 
transduced by DN-Brg1 or YFP control adenovirus. 72 hours after transduction, 
mRNA was harvested and the levels of SRF dependent genes were measured 
by quantitative real time RT-PCR. Transcript level was calculated and presented 
as in figure 1. Data presented are the mean±SEM of 9 samples from 3 
independent experiments. * Indicates statistical significance as determined by a 
student T test (P<0.05). 
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Figure 9. Brg1 forms a complex with SRF and MRTFA in vivo. A. Adenovirus 
encoding HA-tagged SRF and HA-tagged MRTFA were transduced into COS 
cells, 48 hours later, nuclear proteins were harvested using a hypotonic 
lysis/nuclease digestion protocol (Active Motif). Proteins were 
immunoprecipitated using MRTFA (MA), SRF (S) and Brg1 (B) antibodies and 
goat IgG (Ig(G)) or rabbit IgG (Ig(R)) as a negative control. (MRTFA is a goat 
antibody, SRF and Brg1 are rabbit antibodies.) Immunoprecipitated proteins were 
then identified by western blotting, using the antibodies indicated at the right of 
the blot. Inp- 10% of input. B. Co-immunoprecipitations were performed from 
nuclear extracts prepared from A10 cells. C. Mouse bladder tissues were diced 
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into small pieces and homogenized in a pre-chilled homogenizer prior to 
harvesting nuclear protein as described above for cells. Precipitated proteins 
were analyzed by western blotting using antibodies directed against endogenous, 
Brg1, MRTFA and SRF as described in Experimental Procedures. 
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Figure 10. Brg1 binds MRTFA but not SRF in vitro. SRF, MRTFA and Brg1 
proteins were synthesized by using in vitro transcription and translation, as 
described in experimental procedures. The proteins were then incubated 
together as shown at the top of the blot and proteins were immunoprecipitated 
using the antibodies indicted below the blot (IP) (preimm: preimmune serum from 
rabbit used to make MRTFA antibody). The presence of individual proteins in 
each immunoprecipitate was determined by western blotting using antibodies to 
each of their respective epitope tags (indicated at the right of the blot).  10% of 
the input of each IP was loaded at the left of the blot. 
 
 45 
 
 
Figure 11. DN-Brg1 attenuates the ability of MRTFA to increase SRF 
binding to the promoters of smooth muscle-specific genes. B22 cells grown 
in the presence (control) or absence (+DN-Brg1) of tetracycline were transduced 
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with MRTFA or YFP control adenovirus. After 30 hrs, cells were fixed and 
harvested for chromatin immunoprecipitation assays. Chromatin was precipitated 
using an antibody against SRF (left panels), acetylated histone H3 (right panels) 
or using IgG negative control. The precipitated genomic DNA was purified and 
the presence of the promoters of SRF-dependent genes measured by real time 
quantitative PCR, using gene specific primers. A. The increase in SRF or H3Ac 
binding in samples transduced with MRTFA is indicated relative to those 
transduced with YFP. These data were calculated and normalized to input levels 
as follows: Relative SRF/H3Ac binding, RQ=2-ΔΔCt, with ΔDCt= (Ct MRTFA-Ct input)-
(Ct YFP-Ct input) B. The relative inhibition of MRTFA induced SRF or H3Ac binding 
by DN-Brg1 is shown. This was calculated as follows: Relative SRF/H3Ac 
binding, RQ=2-ΔΔCt, with ΔΔCt= (Ct DN-Brg1-Ct input)-(Ct control-Ct input). SRF data shown 
in panels ‘A’ and ‘B’ are the mean±SEM of 7 samples obtained from 3 
independent experiments. H3Ac data shown in panels ‘A’ and ‘B’ are the 
mean±SEM of 4 samples obtained from 2 independent experiments. A one 
sample t-test was performed and the asterisks indicates the results that are 
statistically different from 1 (P<0.05). C. The relative binding of SRF or H3Ac in 
control samples (no DN-Brg1, YFP transduced) is shown for each of the 
promoters indicated. Results were calculated as follows: Relative SRF/H3Ac 
binding, RQ=2- Δct, with ΔCt =Ct SRF IP group-Ct IgG IP group. Results presented are the 
mean±SEM of 4-5 samples. 
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Figure 12. Proposed model describing the regulation of MRTFA/SRF 
activity by Brg1. Upper panels: The telokin promoter is used as an example to 
describe the activation of smooth muscle-specific promoters by MRTFA. In 
unstimulated non-muscle cells the promoter is in a condensed inactive chromatin 
conformation that only permits weak or transient SRF binding (Left panel). Upon 
increased nuclear MRTFA, MRTFA binds to Brg1 and recruits the 
MRTFA/Brg1/HAT (p300?) complex to the weakly bound SRF. The binding of 
Brg1 to acetylated histone tails may also play a role in this recruitment process. 
Once the MRTFA/Brg1/HAT complex is recruited to the promoter, Brg1 utilizes 
the energy derived from hydrolysis of ATP to remodel the chromatin structure, 
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permitting tight binding of SRF (Middle panel). Tightly bound SRF/MRTFA can 
then recruit additional co-activators such as p300, resulting in additional 
chromatin remodeling, facilitating binding of the RNA polymerase complex and 
subsequent activation of transcription (Right panel). Lower panels: On the 
promoters of MRTFA regulated early response genes, such as the SRF gene 
itself, SRF is tightly bound to the promoter under resting conditions (Left panel). 
MRTFA, therefore, does not require Brg1-mediated chromatin remodeling to be 
able to bind to the promoter, recruit co-activators and thereby activate 
transcription (Right panel). 
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Chapter III: The SWI/SNF chromatin remodeling complex regulates 
myocardin-induced smooth muscle-specific gene expression. 
Abstract 
Objective: Transcription regulatory complexes comprising myocardin and serum 
response factor (SRF) are critical for the transcriptional regulation of many 
smooth muscle-specific genes. However, little is known about the epigenetic 
mechanisms that regulate the activity of these complexes. In the current study, 
we investigated the role of SWI/SNF ATP-dependent chromatin remodeling 
enzymes in regulating the myogenic activity of myocardin. Methods and Results: 
We found that both Brg1 and Brm are required for maintaining expression of 
several smooth muscle-specific genes in primary cultures of aortic smooth 
muscle cells. Furthermore, the ability of myocardin to induce expression of 
smooth muscle-specific genes is abrogated in cells expressing dominant 
negative Brg1. In SW13 cells, that lack endogenous Brg1 and Brm1, myocardin 
is unable to induce expression of smooth muscle-specific genes. By contrast, 
reconstitution of wild type, or bromodomain mutant forms of Brg1 or Brm1 into 
SW13 cells restored their responsiveness to myocardin. SWI/SNF complexes 
were found to be required for myocardin to increase SRF binding to the 
promoters of smooth muscle-specific genes. Brg1 and Brm directly bind to the N-
terminus of myocardin in vitro through their ATPase domains, and Brg1 forms a 
complex with SRF and myocardin in vivo in smooth muscle cells. Conclusion: 
These data demonstrate that the ability of myocardin to induce smooth muscle-
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specific gene expression is dependent on its interaction with SWI/SNF ATP-
dependent chromatin remodeling complexes.  
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Introduction 
Smooth muscle cells are important contractile components of the cardiovascular 
system that regulate blood pressure and flow. Vascular smooth muscle cells 
modulate their phenotype in response to extracellular cues during the 
development and progression of a variety of diseases including atherosclerosis 
and hypertension. These diseases are associated with decreased expression of 
proteins required for the normal contractile function of smooth muscle cells (104). 
Understanding the mechanisms that control expression of contractile and 
regulatory proteins in smooth muscle cells is, therefore, an essential step toward 
determining how these processes are altered in pathological conditions. 
 
The interaction of serum response factor (SRF) with the co-activator myocardin is 
a critical determinant of vascular smooth muscle development (81, 107). 
Myocardin null mice lack differentiated smooth muscle cells in the dosal aorta 
and placental vasculature and die around E10 (81).  Myocardin is thus critically 
required for the differentiation of these populations of vascular smooth muscle 
cells. Myocardin does not bind directly to DNA, but interacts with genes via its 
binding to SRF through a basic domain and polyglutamine-rich (poly Q) domain 
in myocardin. Myocardin-bound SRF binds to CArG elements within the 
promoters of many smooth muscle-specific genes (92) and myocardin activates 
transcription of these genes through a strong transcriptional activation domain at 
its C-terminus (134). However, although myocardin is a potent activator of CArG 
box-containing cardiac and smooth muscle-specific genes, it poorly activates 
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SRF-dependent skeletal muscle-specific genes or early response genes such as 
c-fos or Egr-1 (107), yet how myocardin distinguishes smooth muscle-restricted 
genes from other SRF-dependent genes still remains elusive. 
 
The dependence of myocardin on promoter bound SRF poses an interesting 
problem as there is little SRF bound to the promoters of smooth muscle-specific 
genes in nonmuscle cells (91), yet myocardin can induce expression of smooth 
muscle-specific genes in these cells (107). Myocardin also increases SRF 
binding to the promoters of smooth muscle-specific genes within intact chromatin 
(91), although the mechanism underlying this phenomena is unknown. We 
hypothesized that ATP-dependent chromatin remodeling may be required for 
these functions of myocardin, allowing it to increase SRF binding to the 
promoters of smooth muscle-specific genes within chromatin. Recent studies of 
ATP-dependent remodeling enzymes have highlighted crucial roles for these 
proteins in diverse developmental processes (39). Mammalian ATP-dependent 
chromatin-remodeling enzymes belong to the SNF2 family of DNA-dependent 
ATPases, which all have a helicase-like ATPase domain. The best-characterized 
mammalian ATP-dependent chromatin-remodeling complex is the SWI/SNF 
complex (39). Brahma (Brm) or Brahma-like gene 1 (Brg1) are the ATPase 
subunits of the SWI/SNF complex. These proteins have been shown to activate 
or repress expression of genes during myeloid differentiation, erythropoiesis, 
adipogenesis, skeletal muscle myogenesis, liver development and gliogenesis 
(reviewed in (39)). Recently we have also shown that Brg1 and Brm are required 
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for myocardin-related transcription factor A (MRTFA) to induce smooth muscle-
specific genes in nonmuscle cells (149). However, as MRTFA knockout mice do 
not exhibit any major vascular defects (80) the importance of MRTFA-SWI/SNF 
interactions in vascular smooth muscle cells is not clear. 
 
In the current study we found that Brg1 and Brm are essential for maintaining 
expression of smooth muscle-specific genes in vascular smooth muscle cells. 
Brg1/Brm are required for myocardin’s ability to induce expression of smooth 
muscle-specific genes and to increase SRF binding to the promoters of these 
genes. We found that Brg1 forms a complex with myocardin and SRF in vivo and 
directly binds to myocardin in vitro through its ATPase domain. Together, our 
data demonstrate that SWI/SNF ATP-dependent chromatin remodeling 
complexes are required for differentiation of vascular smooth muscle cells.  
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Experimental Procedures 
Mammalian expression and reporter gene assays. Expression plasmids 
encoding human Brg1 (pBJ5-Brg1) and the ATPase-defective variant of Brg1 
(K798R) with an HA tag at their C-terminus were obtained from Dr. Gerald 
Crabtree (Stanford, CA) (75). Expression plasmids encoding human Brg1 and 
K798R mutants with C-terminal Flag tags (pBabe vectors) were obtained from 
Addgene (124). For adenoviral expression cDNAs were removed from the 
pBABE vectors and cloned into pShuttle (Clontech). Brg1 and Brm molecules 
lacking their C-termini (Brg1 truncated at amino acid 1414, Brm at 1344) were 
generated by removing Not I or Afl II fragments from the pShuttle constructs. 
Brg1 and Brm containing mutations in their bromodomains (Brg1 FN1506-7-AA, 
Brm FN1481-2-AA) were generated using the quick change mutagenesis kit 
(Stratagene) with the pShuttle vectors as templates. The mouse full-length SRF 
cDNA was cloned into a modified pShuttle vector (Clontech) encoding an N-
terminal HA tag. The mouse myocardin (long form, equivalent to the cardiac 
enriched isoform) pcDNA3.1-myc/his vector was kindly provided by Dr. Eric N. 
Olson (Southwestern Medical Center, Dallas, TX). This vector was used to 
generate adenovirus in which the myocardin harbors an amino-terminal HA 
epitope tag. A truncated myocardin adenovirus (amino acids 80-935, equivalent 
to the smooth muscle enriched isoform) was also generated harboring an amino-
terminal omni epitope tag. All promoter reporter genes were constructed by 
cloning fragments of promoters into the pGL2B luciferase vector (Promega, 
Madison, WI). The mouse telokin promoter-luciferase reporter gene used 
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includes nucleotides –190 to +181 (T370) of the telokin gene as described 
previously (63, 65). The SM22α-luciferase reporter gene includes nucleotides      
-475 to +61 of mouse SM22α (65). Plasmids were sequenced to verify the 
integrity of the insert. Transfection was carried out as previously described. The 
level of promoter activity was evaluated by measurement of the firefly luciferase 
activity relative to the internal control renilla luciferase activity using the Dual 
Luciferase Assay System essentially as described by the manufacturer 
(Promega, Madison, WI). A minimum of six independent transfections were 
performed and all assays were replicated at least twice. Results are reported as 
the mean ± SEM.  
 
Mouse aortic SMC preparation and RNA interference. Primary mouse aortic 
smooth muscle cells were prepared from aorta dissected from 4-week-old mice 
essentially as described previously (147). For all experiments primary cells were 
trypsinized, and replated at 7 x 104 per well in 12-well plates. 12 h after plating, 
cells were transfected with pre-designed Dharmacon siRNA pools targeting Brg1 
or Brm, as well as a control siRNA pool at final concentration of 50 nM. siRNA 
was delivered using Lipofactamine 2000 (Invitrogen) following the manufacturer’s 
instructions. 36 h after transfection, mRNA was harvested and gene expression 
measured by quantitative real time reverse transcription (RT)-PCR as described 
below.  
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Reverse transcription and quantitative real time PCR (qRT-PCR). Total RNA 
was isolated with TRIzol reagent (Invitrogen). 1 µg of RNA was utilized as a 
template for reverse transcription with random hexamer primers. PCR was 
performed with 2 µl (of 1:10 dilution) of cDNA and SYBR green PCR master mix 
(Abgene) with respective gene-specific primers (See Table 1) using the following 
reaction conditions: 1 cycle: 50°C for 2 min; 1 cycle: 95°C for 2 min; 40 cycles: 
95°C for 15 sec, 60°C for 40 sec; 1 cycle: 95°C for 15 sec, 60°C for 1 min, 95°C 
for 15 sec. All PCR reactions were performed in duplicate on triplicate samples 
obtained from 2-3 independent experiments. Relative gene expression was 
converted with 2-ΔΔct method against an internal control hprt or RPLPO house 
keeping gene as detailed in the Figure legends.  
 
Adenovirus construction and cell infection. Adenovirus constructs were made 
using the Adeno-X vectors essentially followed the manufacturers instructions 
(BD Biosciences) as previously described (150). The recombinant adenovirus 
was packaged in HEK293 cells and amplified to obtain high titer stocks. 3T3 cells 
that inducibly express dominant-negative Brg1 following withdraw of tetracycline 
(B22 cells) were described previously (36). These cells were maintained in the 
complete growth media, comprising DMEM (Cellgro), 10% fetal bovine serum 
(Atlanta Biologicals), 2 mM glutamine (Invitrogen), 75 µg/ml G418, 350 U/ml 
hygromycin B (Fisher), and 2 µg/ml tetracycline (Fisher). Cells were washed 
twice with PBS before passage for experiments requiring growth in media lacking 
tetracycline (36). For adenoviral transduction, B22, SW13, 10T1/2 cells and 
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primary SMC were plated in 6-well plates at a density of 0.3-0.5x105 cells/well 
and grown overnight to 80% confluence (with or without tetracycline for B22 
cells). The next day cells were transduced with adenovirus encoding HA-tagged 
YFP-NLS (Nuclear localized Yellow Fluorescent Protein) or HA-tagged 
myocardin or DN-Brg1 in 10% growth media for 4 hours at 37°C. The adenovirus 
was then aspirated and replaced with 10% growth media. These conditions 
resulted in close to 100% transduction of the cell lines and 50-60% transduction 
of the primary aortic cells. 48 hours following transduction, protein extracts or 
total cellular RNA were prepared from the transduced cells. The protein extracts 
were collected using RIPA buffer, containing a cocktail of protease inhibitors and 
protein concentrations were determined using the BCA Protein Assay Kit (Pierce 
Chemical). The total cellular RNA was isolated using Trizol (Invitrogen) as 
described by the manufacturer.  
 
Western blotting. Western blotting analysis was carried out essentially as 
described previously (62). Antibodies used in this study were against: β-actin 
(Sigma, 1:10,000), Brg1 (Upstate, 1:5000), Brm (Abcam, 1:1000), Egr-1 (Santa 
Cruz, 1:1,000), Flag tag (Sigma, M2, 1:5,000), HA tag (Covance, 1:3,000), c-fos 
(Santa Cruz, 1:1000), MLCK (Sigma, clone K36, 1:10,000), myosin light chain 20 
(LC20, a gift from Dr. Patricia Gallagher, 1:5,000), SM α-actin (Sigma, clone 3A1, 
1:10,000), SM22α (a gift from Dr. Len Adam, 1:6,000), SRF (Santa Cruz, G20X, 
1:10,000), telokin (1:6,000)(51), vinculin (Santa Cruz, 1:5,000).  
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Quantitative chromatin immunoprecipitation assays. Chromatin 
immunoprecipitation assays were performed as described previously (147). 
Cross-linked chromatin was immunoprecipitated with 6 µg of anti-SRF (Santa 
Cruz), anti-Brg1 (Upstate) or rabbit IgG control and bound to ssDNA/protein A 
agarose beads (Sigma). The precipitated DNA was then purified and amplified by 
real time PCR for quantification of the target sequences using SYBR green PCR 
master mix (Abgene) with respective gene-specific primers as described 
previously (147).  
 
Co-immunoprecipitation. For detecting protein-protein interaction in vivo, COS 
cells were transduced with adenovirus encoding HA-tagged SRF and HA-tagged 
myocardin. 24 hours after transduction nuclear protein was harvested from the 
COS cells. Co-immunoprecipitation (Co-IP) assays were performed using a 
nuclear complex Co-IP kit as described by the manufacturer (Active Motif). 250 
µg of nuclear protein extracts were incubated with 3 µg of anti-Brg1 antibody 
(Upstate), anti-SRF antibody (Santa Cruz, G20X), anti-myocardin antibody 
(Santa Cruz, M16), or appropriate IgG controls in 500 µl low salt IP buffer (Active 
Motif), overnight at 4°C. 60 µl of EZview protein A beads (Sigma) were added to 
the mixture for an additional 1 hour with rocking and then wash 6 times with the 
low IP buffer. To examine myocardin/SRF/Brg1 complex formation in SMCs, rat 
aortic A10 smooth muscle cells were infected with adenovirus encoding 
myocardin for 3 days. Nuclear protein was then extracted and immuoprecipitated 
as described above. To examine protein-protein interactions in vitro, the TNT 
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Quick Coupled Transcription/Translation System (Promega) was employed to 
generate proteins in vitro programmed with 1 µg of pcDNA myc/hismyocardin 
(myc tag), pShuttle-Brg1 (flag tag), pShuttle Brm (flag tag) and pShuttle-SRF (HA 
tag) plasmid DNA, respectively, as templates. To define binding domains within 
Brg1, various Brg1 restriction fragments were subcloned into pET28 vector 
(Novagen, Madison, WI). These vectors were utilized as templates to produce T7 
tagged protein in vitro as described above. 20 µl of each reaction product were 
incubated with 3µg SRF antibody (Santa Cruz, G20X) or myocardin antibody 
(Santa Cruz, M16) or appropriate IgG control in 250 µl low salt IP buffer (Active 
motif) overnight at 4°C and then protein A beads were added for an additional 2 
hours. The immunoprecipitated proteins were subjected to Western blotting with 
antibodies against: Flag tag (Sigma, 1:5000), HA-tag (Covance, 1:3,000) or c-
myc (Invitrogen, 1:5000), T7 tag (Novagen, 1:10000).  
 
GST pull-down assays. To characterize the interaction between myocardin and 
Brg1 in vitro, various fragments of each of the proteins were expressed as fusion 
proteins in bacteria. Six myocardin deletion mutants were expressed as 
glutathione S-transferase (GST) fusion proteins. Deletion fragments were 
generated by polymerase chain reaction and then subcloned into pGEX4T 
(Amersham Pharmacia Biotech); all constructs were verified by DNA sequencing. 
The following fragments of myocardin were expressed: (1) NT-myocardin, 
encoding amino acids 1-587; (2) CT-myocardin, encoding amino acids 588-935; 
(3) deletion 1, encoding amino acids 1-220; (4) deletion 2, encoding amino acids 
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221-350; (5) deletion 3, encoding amino acids 351-474; and (6) deletion 4, 
encoding amino acids 475-587; Full-length SRF GST fusion protein was 
expressed as we described in our previous report9. Various Brg1 deletion 
mutants were expressed as fusion proteins with a His tag and T7 epitope tag at 
the amino terminus by polymerase chain reaction and subcloned into pET28 
(Novagen, Madison, WI). The following fragments of Brg1 were expressed: 
deletion 5 encoding amino acids 767-931; deletion 6 encoding amino acids 932-
1084; deletion 7 encoding amino acids1085-1246; deletion 8 encoding amino 
acids 1247-1477. T7 tagged Barx2 protein was produced in bacteria as we 
previously reported (60). In vitro binding experiments were carried out essentially 
as described previously (60). Briefly GST-myocardin fusion proteins were bound 
to glutathione-agarose beads and then incubated with bacterial lysates 
containing Brg1 truncation fusion proteins. After incubation at 4°C for 1 h, 
glutathione-agarose-bound protein complexes were washed three times in lysis 
buffer without bovine serum albumin. Glutathione-agarose-bound proteins were 
then analyzed by Western blotting with T7 antibody (1:10000, Novagen).  
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Results 
Depletion of endogenous Brg1 and Brm in aortic SMCs attenuates 
expression of smooth muscle-specific genes. Previously we have shown that 
the ATP-dependent chromatin remodeling enzymes, Brahma-Related Gene 1 
(Brg1) and Brahma (Brm) play an important role in balancing the ability of 
MRTFA to regulate expression of SRF-dependent smooth muscle-specific genes 
and immediate early genes (147). However, as MRTFA knockout mice have not 
been reported to exhibit any vascular defects (80) the importance of MRTFA-
SWI/SNF interactions in vascular SMCs is not clear. We therefore examined the 
functional role SWI/SNF in vascular SMCs. siRNA-mediated knockdown of Brg1 
or Brm in primary mouse aortic SMCs attenuated expression of telokin, calponin 
and smooth muscle myosin heavy chain (SM MHC), late markers of smooth 
muscle differentiation, by approximately 40%. In contrast, knockdown of Brg1 or 
Brm had a lesser effect on expression of the early markers of smooth muscle 
differentiation, SM22α or SM α-actin (Figure 13). Silencing Brg1 also led to a 
30% reduction in expression of endogenous Brm although Brm knockdown did 
not affect Brg1 expression. This is not a result of cross reactivity of siRNA 
molecules as similar results were obtained with multiple siRNA duplexes, with 
DN-Brg1 and in Brg1 knockout cells (data not shown), suggesting that Brm 
expression is at least partially dependent on Brg1 in smooth muscle cells. 
Surprisingly, knockdown of both Brg1 and Brm together did not result in any 
further attenuation of smooth muscle-specific genes, as compared to knockdown 
of either protein alone (Figure 13). These data suggest that Brg1 and/or Brm are 
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important for maintaining expression of genes that are late differentiation markers 
of vascular SMCs.  
 
DN-Brg1 represses activation of smooth muscle-specific genes by 
myocardin. As myocardin has been shown to be critical for vascular smooth 
muscle differentiation we next sought to determine if myocardin requires 
SWI/SNF to induce expression of smooth muscle-specific genes. For these 
experiments we utilized 10T1/2 embryonic fibroblasts and primary cultures of 
aortic smooth muscle cells, two well established systems in which myocardin has 
been shown to induce expression of smooth muscle-specific genes. To inhibit 
SWI/SNF activity, cells were transduced with adenovirus expressing an ATPase 
deficient mutant of Brg1 (K798R) that acts as a dominant negative (36). 
Consistent with previous reports, adenoviral-mediated expression of myocardin 
in 10T1/2 and primary aortic SMC cells resulted in induction of endogenous 
telokin, smMHC, calponin, SM22α and SM α-actin mRNA (Figure 14A, B). 
Expression of dominant negative Brg1 significantly attenuated the induction of 
telokin, smMHC, calponin, and SM22α by myocardin in 10T1/2 cells and aortic 
SMCs (Figure 14). In contrast, DN-Brg1 slightly augmented myocardin’s ability to 
activate SRF itself and did not significantly affect the activation of c-fos in aortic 
SMC (Figure 14B). Similar results were also seen in NIH3T3 cells induced to 
express a dominant negative Brg1 (Figure 15). Interestingly DN-Brg1 also 
attenuated the ability of myocardin to induce the expression of the cardiac-
specific ANF and cardiac α-actin genes in 10T1/2 cells (Figure 14A).  
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Previous reports have shown that transient over-expression of wild-type Brg1 can 
increase the activity of SWI/SNF-dependent reporter genes, while expression of 
a dominant negative Brg1 decreases the activity of these reporter genes through 
formation of inactive SWI/SNF complexes (33, 75). We therefore determined if 
DN-Brg1 could directly affect myocardin’s ability to activate the telokin and 
SM22α promoters. Luciferase reporter assays revealed that over-expression of 
DN-Brg1 in NIH3T3 cells attenuated myocardin’s activation of telokin and SM22α 
promoter reporter constructs (Figure 15). Taken together, data presented here 
demonstrate that dominant negative Brg1 can attenuate myocardin’s ability to 
induce expression of many smooth muscle-specific genes in both nonmuscle and 
smooth muscle cells. By contrast, dominant negative Brg1 either did not affect or 
augmented myocardin’s ability to activate other SRF target genes such as SRF 
itself or c-fos. 
 
Induction of endogenous smooth muscle-specific genes by myocardin 
requires Brg1/Brm ATPase activity but does not require their 
bromodomains. To formally confirm that the ATPase activity of Brg1 and Brm is 
required to support myocardin’s myogenic activity we utilized SW13 cells, an 
adenocarcinoma cell line that expresses no endogenous Brg1 or Brm (97) 
(Figure 16). In these cells myocardin fails to induce expression of most smooth 
muscle-specific proteins (Figure 16A, B, left four lanes). Only SM α-actin 
induction could be detected. Co-transfection of SW13 cells with myocardin 
together with wild type Brg1 or Brm expression plasmids restored myocardin’s 
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ability to induce expression of smooth muscle-specific proteins such as SM22α, 
telokin, and smMLCK (Figure 16). In contrast, the dominant negative, ATPase 
deficient Brg1 could not restore myocardin’s myogenic activity (Figure 16A, ‘DN’ 
lanes). Both Brg1 and Brm contain a bromodomain toward their c-termininal that 
has been shown to be able to interact with acetylated histones (127). To 
determine if Brg1/Brm-acteylated histone interactions are important for 
supporting myocardin’s myogenic activity, mutant Brg1/Brm molecules were 
generated that either completely lacked the c-terminus, including the 
bromodomains or that harbored two specific amino-acid mutations within the 
bromodomain (Brg1 FN1506-7-AA, Brm FN1481-2-AA). Mutation of these residues 
has been previously shown to inhibit the binding of Brg1 to acetylated histones 
(123). These mutants were able to support myocardin’s myogenic activity similar 
to the wild type molecules, indicating that the bromodomains of Brg1 or Brm are 
not required for this activity (Figure 16). These data also demonstrate that both 
Brm and Brg1 have similar abilities to support myocardin’s myogenic activity 
(Figure 16B, compare the Brg1 WT lanes to the Brm WT lanes). Although 
identical amounts of myocardin plasmid were used in all co-transfections the 
resultant myocardin expression levels varied depending on which Brg1/Brm 
plasmid was co-transfected into the cells (Figure 16). This likely reflects 
differences in transfection efficiencies of specific plasmid mixtures. In general, 
the extent of induction of smooth muscle-specific genes by myocardin reflected 
the relative levels of myocardin expression. However, in cells transfected with the 
DN-Brg1 even high levels of myocardin failed to induce expression of smooth 
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muscle-specific genes (Figure 16A). This latter finding further demonstrates that 
the ATPase activity of Brg1 is required to support myocardin’s myogenic activity. 
 
DN-Brg1 inhibits myocardin’s ability to increase SRF binding to the 
promoters of smooth muscle-specific genes. Previous studies have shown 
that in nonmuscle cells there is little SRF bound to the promoters of smooth 
muscle-specific genes but introduction of myocardin into these cells leads to 
increased SRF binding (91). Similarly we have previously shown that MRTFA 
increases SRF binding to the promoters of smooth muscle-specific genes and 
this process is attenuated by DN-Brg1 (147). We thus sought to determine if Brg1 
is also required for myocardin to increase SRF binding to the promoters of 
smooth muscle-specific genes within intact chromatin. In agreement with 
previous reports (91), using quantitative ChIP assays we observed enhanced 
SRF binding to the telokin, SM22α and SM α-actin promoters but not the c-fos 
and SRF promoters following myocardin transduction into NIH 3T3 cells (Figure 
17A). Expression of DN-Brg1 attenuated this myocardin-induced increase in SRF 
binding to the telokin and SM22α promoters without significantly affecting SRF 
binding to the SM a-actin, SRF and c-fos promoters (Figure 17B). ChIP assays in 
differentiated primary SMCs also revealed Brg1 binding to the promoters of 
smooth muscle-specific genes under control conditions (Figure 17C). In addition, 
expression of DN-Brg1 in differentiated SMCs significantly inhibited the binding of 
endogenous SRF to the promoters of the telokin and SM MHC gene but not the 
SRF or SM22α genes (Figure 17D). These data are consistent with expression 
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data shown in Figure 13 that demonstrate that the later markers of smooth 
muscle differentiation such as telokin and smMHC are most dependent on 
Brg1/Brm. 
 
Brg1, myocardin and SRF form a complex in vivo. To determine if Brg1 
interacts with myocardin/SRF complexes in vivo, immunoprecipitation assays 
were performed from COS cells transduced with adenoviruses encoding 
myocardin and SRF (Figure 18A). Brg1 immunoprecipitates were found to also 
contain myocardin and SRF. Similarly, SRF immunoprecipitates also contained 
Brg1 and myocardin. In rat aortic A10 SMCs, myocardin immunoprecipitates also 
contained SRF and Brg1 (Figure 18B). These data suggest that, either Brg1, 
myocardin and SRF exist in a single complex in vivo or that Brg1 binds to both 
myocardin and SRF. To distinguish these possibilities co-immunoprecipitation 
assays were performed using proteins generated in vitro.  Results from these 
experiments demonstrated that Brg1 and Brm directly bind to myocardin but not 
to SRF (Figures 18C,D). When Brg1 or Brm were incubated with myocardin they 
could be co-immunoprecipitated with myocardin. In contrast, when Brg1 or Brm 
were incubated with SRF they were not co-immunoprecipitated with SRF. No 
endogenous SRF, myocardin and Brg1 were detected in the in vitro translation 
reaction system (data not shown).  
 
The ATPase domain of Brg1 binds to N-terminus of myocardin. Co-
immunoprecipitation assays using in vitro transcribed and translated myocardin 
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and fragments of Brg1 revealed that the region from amino acids 837 to 1446 of 
Brg1 binds to myocardin (Figure 19). To further resolve the myocardin binding 
site within this region, an additional series of Brg1 deletion mutants were 
generated, expressed in bacteria and used in GST-pulldown assays with the N-
terminus of myocardin as bait (Figure 19). These assays demonstrate that the 
ATPase domain of Brg1 extending from amino acids 767-931 is sufficient to bind 
to myocardin. Interestingly this region is 94% identical between Brg1 and Brm, 
consistent with our observations that both of these molecules can bind to 
myocardin (Figure 18C,D). GST-pulldown assays were also performed to 
determine which portion of myocardin interacts with Brg1 (Figure 19). Data from 
these experiments demonstrated that the Brg1 interacts with the N-terminal 
portion of myocardin, with the region spanning the basic and poly Q domains 
(myo D2-GST in Figure 19E) having the highest apparent affinity. The GST-
pulldown assays also confirm that Brg1 does not directly bind to SRF, while 
Barx2 can be readily detected bound to GST-SRF fusion proteins, as reported 
previously (60). 
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Discussion 
Our data demonstrate that the ability of myocardin to induce expression of most 
smooth muscle-specific genes is regulated by the activity of the SWI/SNF ATP-
dependent chromatin remodeling complex. We suggest a model in which 
myocardin associates with the SWI/SNF complex through direct binding to the 
Brg1 or Brm ATPase subunit. This association is required in order for myocardin 
to increase SRF binding to the promoters of smooth muscle-specific genes within 
intact chromatin, thereby leading to activation of these genes during 
differentiation of vascular smooth muscle cells.  
 
Although Brg1/Brm containing SWI/SNF complexes are required for myocardin to 
induce expression of many smooth muscle-specific genes the induction of SM α-
actin by myocardin was largely independent of SWI/SNF (Figures 13-16). In 
addition, in SW13 cells that lack Brg1 and Brm, myocardin was still able to 
induce SM α-actin expression (Figure 16A). This correlates with the relatively 
high basal levels of SM α-actin expression in many of these cells in the absence 
of added myocardin. Thus it is likely that the SM α-actin promoter is already in an 
active transcriptionally favorable conformation in the absence of myocardin. This 
may suggest that the SWI/SNF complex is dispensable for myocardin-induced 
activation of genes, such as SM α-actin, in cells in which these genes are already 
transcriptionally active. In contrast, SWI/SNF activity is required for myocardin to 
induce expression of genes that are otherwise transcriptionally silent in a given 
cell type. Similar to SM α-actin expression of SM22α in primary smooth muscle 
 69 
 
cells was found to be largely independent of Brg1. This may also reflect the 
contribution of myocardin independent pathways in driving chromatin remodeling 
and transcription of the SM22α locus in smooth muscle cells. For example, both 
SM α-actin and SM22α can be induced by TGFβ in 10T1/2 cells by a myocardin 
independent pathway (1, 28). This model is, however, likely to be an over-
simplification, as in primary cultures of mouse aortic smooth muscle cells we 
observed that the myocardin-induced increase in expression of smooth muscle-
specific genes was at least partially attenuated by DN-Brg1 (Figure 14B). As all 
of the genes examined were expressed prior to myocardin over-expression, this 
may suggest that even if a gene is transcriptionally active, SWI/SNF induced 
changes in chromatin can further augment myocardin’s myogenic activity. 
 
Domain mapping experiments suggest that Brg1 and Brm interact with the region 
of myocardin that spans the SRF interaction domain (basic and poly Q region). 
Despite the overlapping binding sites, co-immunoprecipitation studies show that 
myocardin is present in a complex that includes both Brg1 and SRF within intact 
cells. The Brg1 binding site in myocardin is present in both the long, cardiac-
selective isoform (1-935) and the shorter, smooth muscle-selective isoform (80-
935). These results suggest that both cardiac- and smooth muscle-selective 
myocardin isoforms will interact with and be regulated by SWI/SNF. In support of 
this proposal, the myogenic activity of both the cardiac myocardin (Figure 15), 
and the smooth muscle myocardin (Figures 14,16) was attenuated by dominant 
negative Brg1. In addition, the ability of myocardin to induce expression of 
 70 
 
cardiac-specific genes in 10T1/2 cells was also attenuated by DN-Brg1. These 
observations suggest that the myogenic activity of myocardin both in the heart 
and in vascular SMCs is regulated by SWI/SNF. 
 
Results from experiments in which we reconstituted Brg1 or Brm expression in 
SW13 cells suggest that either wild-type Brg1 or Brm containing SWI/SNF 
complexes are equally effective at supporting myocardin’s myogenic activity 
(Figure 16). In addition, knockdown of either Brg1 or Brm in aortic SMCs 
attenuated expression of smooth muscle-specific genes (Figure 13) and both 
Brg1 and Brm can directly bind to myocardin in vitro (Figure 18C and D). These 
data suggest that Brg1 or Brm containing SWI/SNF complexes may both play 
important roles in smooth muscle cells. In contrast to myocardin, the LIM domain 
protein CRP2 has recently been shown to interact specifically with Brg1, but not 
Brm, in order to induce expression of smooth muscle-specific genes in 
cardiomyocytes (24). Despite the ability of either Brg1 or Brm to support 
myocardin’s myogenic activity in SW13 cells, knocking-down both Brg1 and Brm 
in smooth muscle cells did not result in any further attenuation of smooth muscle-
specific genes as compared to knockout of either protein alone (Figure 13). The 
lack of an additive effect of the double knockdown, may suggest that Brg1- and 
Brm-containing SWI/SNF complexes act together in smooth muscle cells to 
regulate myocardin. This must however, be interpreted with caution as 
knockdown of Brg1 also attenuated expression of Brm. Further studies analyzing 
tissue specific single or double knockouts of Brg1 and Brm, in vivo, will be 
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required to clarify the role of individual SWI/SNF complexes in regulating smooth 
muscle differentiation.  
 
In addition to ATP-dependent chromatin remodeling complexes, enzymes that 
covalently modify histones are important to mediate myocardin activation of 
smooth muscle-specific genes (17, 35). For example, myocardin has been shown 
to bind to p300 and to promote acetylation of histones associated with the 
promoters of smooth muscle-specific genes (17, 91). As the bromodomains of 
Brg1 and Brm are known to bind to acetylated histones we initially speculated 
that myocardin-recruited HAT activity may help recruit SWI/SNF to promote 
transcriptional activation of genes in smooth muscle cells. However, data 
showing that the bromodomains of Brg1 and Brm are not important for supporting 
myocardin’s myogenic function argue against this proposal (Figure 16). Similarly, 
it is unlikely that direct DNA binding by the AT-hook domain of Brg1 or Brm is 
required to recruit myocardin to chromatin, as the C-terminal truncation of Brm 
that we analyzed also lacks this domain (12) yet was still able to support 
myocardin’s myogenic activity (Figure 16).  
 
In skeletal muscle, weak binding of MyoD to the myogenin promoter via MyoD 
interactions with Pbx, facilitates SWI-SNF recruitment through direct binding of 
MyoD and Brg1 (10, 38). Chromatin remodeling by SWI/SNF then facilitates tight 
binding of MyoD to the E box within the myogenin promoter, facilitating promoter 
activation and skeletal muscle cell differentiation. By analogy we propose a 
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model in which in undifferentiated SMC or in nonmuscle cells, SRF has a low 
binding affinity for CArG box elements in the promoters of smooth muscle-
specific genes within intact chromatin. Little transcription activity of smooth 
muscle-specific genes such as telokin and SM-MHC, thus occurs in these cells. 
To induce smooth muscle differentiation, myocardin complexed with p300 and 
SWI/SNF, interacts with SRF weakly bound to the promoters of smooth muscle-
specific genes. SWI/SNF binding to the promoter regions then leads to ATP-
dependent chromatin remodeling and rearrangement of the nucleosomes that 
facilitates tight binding of SRF. This may also allow binding of additional 
activators to the adjacent DNA segments. These activators, together with the 
SRF/myocardin/p300 complex can then further modify chromatin to facilitate 
recruitment of general transcriptional factors, including RNA polymerase II, 
resulting in transcriptional activation of smooth muscle-specific genes.  
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Figure 13. Effects of depletion Brg1 or Brm on expression of endogenous 
smooth muscle-specific genes. Mouse aortic smooth muscle cells were 
transfected with pre-designed Dharmacon siRNA smart pools targeting Brg1 or 
Brm, as well as a control siRNA, at final concentration of 50 nM. 36 h after 
transfection, mRNA was harvested and the levels of Brg1, Brm and smooth 
muscle marker genes were measured by quantitative real time RT-PCR as 
indicated in each panel. Data presented are the mean±SEM of 6 samples from 2 
independent experiments and expression levels were normalized to an hprt 
internal control and are expressed relative to levels in siRNA control samples (set 
to 1). * Indicates statistical significance as determined by a student T test 
(P<0.05). 
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Figure 14. DN-Brg1 abrogates the induction of smooth muscle-specific 
genes by myocardin. A. 10T1/2 cells were transduced with DN-Brg1 or control 
YFP adenovirus together with myocardin (solid bars) or YFP (open bars) 
adenovirus. 48 hrs following transduction total RNA was harvested and analyzed 
by qRT-PCR. Transcript levels was firstly normalized to hprt internal loading 
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control and then normalized to their respective YFP control group. RQ=2-ΔΔCt and 
ΔΔCt = (Ct experimental-Ct hprt)- (Ct control-Ct hprt). Data presented are the mean±SEM of 
6 samples obtained from 2 independent experiments. B. Primary mouse aortic 
smooth muscle cells were transduced by DN-Brg1 or YFP control adenovirus 
with or without myocardin adenovirus as described in “A” (transduction efficiency 
of these cells was approximately 50-60%). 36-48 hours after transduction, cells 
were lysed, mRNA harvested and transcript levels analyzed as described above. 
Data presented are the mean±SEM of 3 samples obtained from one experiment. 
Similar results were obtained in a replicate experiment. 
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Figure 15. Dominant negative Brg1 blocks the induction of endogenous 
smooth muscle-specific genes by myocardin. A. B22 cells were grown in the 
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presence (control) or absence (DN-Brg1) of tetracycline for 24 hours. Cells were 
then transduced with HA-tagged myocardin (solid bars) or HA-tagged YFP (open 
bars) adenoviruses and maintained in their respective media for 30 hours. Total 
cellular mRNA was isolated, reverse transcribed and the levels of gene 
expression were measured by quantitative real time PCR. Transcript levels were 
first normalized to acidic ribosomal phosphoprotein PO (RPLPO) internal loading 
control and then normalized to their respective YFP control group. RQ=2-ΔΔCt 
and ΔΔCt = (Ct experimental-Ct RPLPO)-(Ct control-Ct RPLPO). Data presented 
are the mean±SEM of 8-9 samples obtained from 3 independent experiments. * 
Indicates statistical significance as determined by a student T test (P<0.05). B. 
B22 cells were treated as described in panel A except that protein extracts were 
prepared using RIPA lysis buffer and protein expression levels analyzed by 
Western blotting. C. Luciferase reporter assays were performed in B22 cells in 
presence (+, no tetracycline) or absence (−, with tetracycline) of DN-Brg1 
(K798R) following transfection of myocardin or empty expression plasmids as 
indicated. Data presented are the mean±SEM of 6-9 samples obtained from 3 
independent experiments. * Indicates statistical significance as determined by a 
student T test (P<0.05). 
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Figure 16. Re-introduction of wild type Brg1 or Brm, but not an ATPase 
deficient mutant, into SW13 cells restores myocardin’s ability to induce 
expression of smooth muscle-specific genes. SW13 cells grown in 6-well 
plates were co-transfected with expression plasmids (1 µg) encoding either wild 
type Brg1 (WT) and Brm, DN-Brg1 (DN), CT-truncated Brg1 or Brm (DCT) or 
bromodomain mutant (BD) of Brg1 and Brm, together with myocardin expression 
plasmid (1 µg, except in the absence of the Brg/Brm plasmid where 2 µg were 
used), as indicated at the top of the panel (-, empty expression plasmid). 36 
hours after transfection protein expression was analyzed by western blotting with 
the indicated antibodies. Exogenous Brg1 and Brm were detected with anti-Flag 
antibodies (Flag) and exogenous smooth muscle myocardin was detected with 
an omni-epitope tag antibody (Myo(Omni)). 30 µg of protein were loaded in each 
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lane. The blots shown are representative of data obtained from 2 separate 
experiments. The Brm WT sample shown in panel ‘A’ is the same sample as 
shown in the first WT lane of panel ‘B’. Similarly the WT Brg1 samples shown in 
panel ‘B’ are the same samples as those shown in panel ‘A’.  
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Figure 17. DN-Brg1 blocks the ability of myocardin to increase SRF 
binding to the promoters of smooth muscle-specific genes within 
chromatin. A-B. B22 cells  (an NIH3T3 cells line that inducibly express DN-Brg1 
in response to tetracycline withdrawal (36)) grown in the presence (control) or 
absence (induced DN-Brg1) of tetracycline were transduced with myocardin or 
YFP control adenovirus. After 30 hrs, cells were fixed and harvested for 
chromatin immunoprecipitation assays. Chromatin was precipitated using an 
antibody against SRF or using IgG negative control. The precipitated genomic 
DNA was purified and the presence of the promoters of SRF-dependent genes 
measured by real time PCR using gene specific primers (147). A. The increase in 
SRF binding in samples transduced with myocardin is indicated relative to those 
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transduced with YFP. These data were calculated and normalized to input levels 
as follows: Relative SRF binding=2-ΔΔCt, with ΔΔCt= (Ct myocardin-Ct input)-(Ct YFP-Ct 
input). B. The relative inhibition of myocardin induced SRF binding by DN-Brg1 is 
shown. This was calculated as follows: Relative SRF binding= 2-ΔΔCt, with ΔΔ4Ct= 
(Ct DN-Brg1+Myocardin-Ct input)-(Ct YFP+Myocardin-Ct input). Data shown in panels ‘A’ and ‘B’ 
are the mean±SEM of 7 samples obtained from 3 independent experiments. A 
one-way T test was performed and the asterisks indicate the results that are 
statistically different from 1 (P<0.05). C-D. Primary colon smooth muscle cells 
were prepared from 4 week old mice. The cells were transduced by DN-Brg1 or 
YFP control adenovirus. After 36 hours, cells were fixed and harvested for 
chromatin immunoprecipitation assays as above. C. The relative Brg1 binding to 
several SRF dependent genes in control primary smooth muscle cells is shown. 
The Brg1 binding to promoters were normalized to IgG control.  The relative Brg1 
binding was calculated as RQ=2-ΔCt, with ΔCt= Ct Brg1-Ct IgG. D. The relative 
inhibition of SRF binding by DN-Brg1 is shown. The inhibition of SRF binding by 
DN-Brg1 is calculated as, RQ=2-ΔΔCt, with ΔΔCt= (Ct DN-Brg1-Ct input)-(Ct YFP-Ct input). 
Data presented are the mean ±SEM of 4 samples. 
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Figure 18. Myocardin, SRF and Brg1 form a complex in vivo and Brg1 binds 
directly to myocardin in vitro. A. COS cells were transduced with HA-tagged 
myocardin and HA-tagged SRF adenovirus. After 24 hours, nuclear protein was 
harvested and proteins were immunoprecipitated using Brg1, SRF or control IgG 
antibodies, as indicated. Immunoprecipitated proteins were identified by Western 
blotting using antibodies against Brg1 or the HA-epitope tags on myocardin and 
SRF as indicated at the right of the blot. B. A10 SMCs were transduced with 
omni-tagged myocardin for 24 hours. Nuclear protein was harvested and 
subsequently immunoprecipitated using myocardin or control IgG antibody. C. 
SRF, myocardin, and Brg1 or Brm (D) were transcribed and translated in vitro, 
the expressed proteins were then incubated together (SRF+Brg1/Brm or 
myocardin +Brg1/Brm) as indicated at the top of the blots. Protein mixtures were 
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immunoprecipitated with myocardin, SRF or IgG control antibodies, as indicated 
below the blots. The precipitated proteins were analyzed by western blotting, 
using antibodies indicated at the right of the blots. On all blots ‘input’ lanes 
represent 10% of the inputs that were mixed together and used for 
immunoprecipitates. 
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Figure 19. Brg1 ATPase domain binds to the amino-terminus of myocardin. A. 
Schematic illustration of the domain structures of Brg1 and myocardin indicating 
the location of the truncation mutants used for mapping studies. NTD: N-terminal 
domain, ++: basic domain, Q: poly Q domain, LZ: leuzine zipper domain, TAD: 
transcriptional activation domain. B. Myocardin and T7-tagged Brg1 truncation 
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mutants were transcribed and translated in vitro, the expressed proteins were 
then incubated and immunoprecipitated with myocardin antibody. The 
precipitated proteins were detected by western blotting, using an anti-T7 
antibody. C. A GST-fusion protein comprising the N-terminus of myocardin was 
conjugated to GSH beads and incubated with T7-tagged Brg1 fragments 
expressed in bacteria. Bound proteins were identified by western blotting using a 
T7 antibody. D. GST-fused to NT- or CT-myocardin, SRF or GST alone were 
expressed in bacteria, conjugated to GSH beads and incubated with bacterial 
expressed T7-tagged Brg1Δ3 or Barx2 as indicated. A western blot of the GST-
bound proteins is shown in the upper panel, the lower panels show the 
expression of the GST-fusion proteins (marked by an asterisks to the left of each 
protein). E. Myocardin-GST fusion proteins or GST alone was conjugated to GSH 
beads and incubated with in vitro translated T7-tagged Brg1Δ3. GST pull-down 
assay was performed as described above.  
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Chapter IV: The role of Brg1/Brm in smooth muscle development in vivo 
Abstract  
We have shown that Brahma-related gene 1 (Brg1) or Brahma (Brm), the ATP 
dependent chromatin remodeling enzymes in SWI/SNF complexes, are required 
for MRTFs myogenic induction function and for primary smooth muscle cells to 
maintain their high levels of smooth muscle contractile protein expression. 
However, our previous studies have only used cultured cells to explore the 
myogenic functions of Brg1 and Brm. The role of Brg1/Brm in smooth muscle 
development in vivo is still unknown. We have obtained or generated Brm global 
KO mice, smooth muscle-specific Brg1 KO mice and smooth muscle-specific 
Brg1KO/global Brm null (double KO) mice and analyzed the phenotypes of these 
mice. Results showed that both Brg1 SM-specific KO mice and Brm global KO 
mice had normal smooth muscle contractile protein expression, while Brg1/Brm 
double KO had significantly decreased levels of contractile proteins. These 
results suggest that Brg1 and Brm play redundant roles in regulating smooth 
muscle contractile protein expression during GI development in vivo. The other 
developmental defects in Brg1 KO, Brm KO and Brg1/Brm double KO mice will 
be discussed in the next chapter. 
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Introduction 
As discussed in the last two chapters we have shown that SWI/SNF ATP-
dependent chromatin remodeling complexes containing either Brahma-related 
gene 1 (Brg1) or Brahma (Brm) ATPase subunits are required to maintain SRF-
dependent SM-specific contractile protein expression in primary colon, bladder 
and aorta SMCs. (147, 152). In vitro, in cultured SMC knockdown of Brg1 or Brm 
attenuated expression of smooth muscle-specific contractile proteins (152). This 
result suggests that either there are non-overlapping roles of Brg1 and Brm or 
that the combined total level of expression of Brg1 and Brm is required to 
maintain SRF-dependent SM-specific contractile proteins expression in SMCs. In 
support of this latter possibility, we also found that either Brg1 or Brm alone were 
sufficient to support the myogenic activity of two important SRF co-factors, 
MRTFA and myocardin. MRTFs cannot induce expression of SM-specific 
contractile proteins in SW13 cells that lack both Brg1 and Brm, while 
reintroducing either Brg1 or Brm alone into these cells restored the myogenic 
activity of MRTFs. This result suggests Brg1 and Brm have overlapping 
redundant roles in regulating the induction of SRF-dependent SM-specific 
contractile protein genes. Alternatively, it is possible that both Brg1 and Brm are 
required to maintain the differentiation status of SMCs, while either over-
expressed Brg1 or Brm alone is sufficient to support the myogenic activity of 
over-expressed MRTFs in none muscle cells. These findings highlight the need 
to determine the role of Brg1 and Brm in vivo under physiological conditions of 
SM differentiation and development.  
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Brg1 and Brm are ubiquitously expressed in almost all tissues, including SM 
(data not shown). Brg1 KO mice die during the periimplantation stage before SM 
differentiation (15), thus the function of Brg1 in SM development cannot be 
determined from the global Brg1 KO mice. On the other hand Brm knockout mice 
develop normally, except that adult mice have higher body weight as compared 
to wild type littermates (112). However, no reports have examined the phenotype 
of smooth muscle tissues in the Brm null mice, although the phenotypes of these 
global knockout mice suggest that Brg1 and Brm have at least some specific 
non-redundant roles during mammalian development. 
 
To fill the void in our knowledge of the role of Brg1 and Brm in SM development, 
and to specifically investigate the possible redundant role of these two molecules 
in supporting smooth muscle differentiation, we have obtained or generated Brm 
KO mice, smooth muscle-specific Brg1 KO mice and smooth muscle-specific 
Brg1 KO/global Brm null mice and analyzed the phenotypes of these mice. From 
this analysis we found that both Brg1 SM-specific KO mice and Brm global KO 
mice had normal smooth muscle contractile protein expression, while Brg1/Brm 
double KO mice showed severe gut defects associated with decreased 
contractile protein expression. These results suggest that Brg1 and Brm play 
redundant role in regulating smooth muscle contractile protein expression during 
GI development in vivo. They also demonstrate that the SWI/SNF complex plays 
a critical role in GI smooth muscle development. 
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Methods and Materials 
Generation of smooth muscle specific Brg1 knockout mice. Brg1flox/flox mice 
(obtained from Dr. C-P Chang at Stanford), were bred with smMHCcre/eGFP 
mice (from Dr. Kotlikoff at Cornell) (139) in order to generate a smooth muscle-
specific knockout of Brg1 mice. In smMHCCre/eGFP mice, cre recombinase is 
expressed under the control of the smooth muscle-specific smMHC promoter 
(139). Brg1flox mice were used on a mixed Sv129/C57B6 background.  The male 
heterozygous Brg1flox/+:smMHCCre/eGFP-/+ mice were bred with female 
Brg1flox/flox mice to generate a smooth muscle-specific Brg1 knockout mice 
(Brg1flox/-: smMHC-Cre-/+)(Figure 1a). Because of a transient expression of Cre in 
the sperm of the Brg1flox/+: smMHCCre-/+ mice(41) the floxed allele transmitted 
from these mice is recombined resulting in a global heterozygous null allele of 
Brg1 in all tissues. There are thus four possible genotypes of the offspring: 
Brg1flox/-:smMHC-Cre-/+ (SM-specific Brg1 KO with global heterozygous Brg1 
background, in this paper, we use “Brg1 KO’’ to refer to this genotype), Brg1flox/-: 
smMHC-Cre-/- (global Brg1 heterozygous, which we use as a control for the KO 
mice), Brg1flox/+: smMHC-Cre-/+ (SM-specific Brg1 heterozygous) and Brg1flox/+: 
smMHC-Cre-/- (wild type). 
 
Generating Brg1/Brm double knockout mice.  
Brg1/Brm double knockout mice were generated by crossing the Brg1f/f mice and 
smMHC-cre mice with Brm null mice as indicated in Figure 5A. Brm null mice 
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originally generated by Dr. M. Yaniv’s group (112) have been obtained from Dr. 
Scott Bultman.  
 
Genotyping  
Mouse digits were cut and digested in 10 µl lysis buffer (25 mM NaOH and 0.2 
mM EDTA) 95°C for 30 min. 100 µl of neutralization buffer (40 mM TrisHCl) was 
added and the resulting samples, containing genome DNA, were analyzed by 
PCR (95°C 2 min, 95°C 1 min, 58°C 30 sec and 73°C 1.5 min for 40 cycles, 73°C 
10 min). Primers used were as indicated in table 4. 
 
β-Galactosidase staining: β-Gal staining was performed as reported previously 
(129). Briefly, tissues were carefully dissected out and wash in cold phosphate-
buffered saline (PBS). Then tissues were fixed in 2% paraformaldehyde/0.2% 
glutaraldehyde in PBS for 1 h on ice followed by washing with cold PBS.  After 
washing, tissues were stained overnight with gentle rocking in X-Gal stain mix 
(0.5 mg/ml X-Gal, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 2 mM MgCl2, 0.2% 
Nonidet-P 40, 0.2% Tween 20, and 0.2% Triton X-100 in PBS). Next day, tissues 
were washed in PBS and fixed in 4.0% paraformaldehyde overnight. The fixed 
tissues were cleared with methyl-salacilate and photographed (Pixelink camera) 
under a dissecting microscope. 
 
Immunofluorescence staining. Immunofluorescence staining was performed 
essentially as described previously (129). Tissues were dissected and incubated 
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in 20% sucrose overnight. After cryoprotection, tissues were frozen in embedding 
medium (O.C.T., Optimal Cutting Temperature, from Tissue-Tek) and 6-8 µm 
sections were obtained and stored at -80°C until use. For immunofluorescent 
analysis of protein expression sections were fixed in 3.7% formaldehyde and 
stained with primary antibodies: Brg1 (Santa Cruz, 1:100), SM1 and SM2 (61), 
telokin (50), cleaved caspase3 (Cell Signaling, 1:50), Ki67 (Dako, M7249, 1:25). 
Sm α-actin conjugated with FITC (Sigma, 1:500). Primary antibodies were 
detected using fluorescein-conjugated anti-rabbit, anti-rat or anti-mouse IgG. 
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Results 
To verify that the smMHC Cre transgene mediates appropriate smooth muscle-
specific Cre recombinase activity we crossed the smMHC-Cre mice with 
ROSA26floxstopfloxLAC (a Cre-dependent LAC reporter strain) mice. Analysis of β-
galactosidase activity in these mice shows heterozygous Cre expression is 
sufficient to efficiently mediate recombination of the ROSA26 reporter allele 
(Figure 20B) in SM tissues. Importantly this recombination was also restricted to 
smooth muscle tissues with the exception of some expression in the cardiac 
atria. To confirm that the transgene also mediates SM-specific recombination of 
the Brg1 locus, we extracted genomic DNA from SM-specific Brg1 heterozygous 
mice (Brg1flox/+: smMHC-Cre-/+) and detected the recombined allele by PCR. 
Primers (112) that only amplify the recombined Brg1 locus were used to perform 
real time PCR. Results showed that Brg1 locus was only recombined in SM 
containing tissues (bladder, colon and ileum), but not in non-SM tissues (colon 
epithelium, skeletal muscle, heart, liver, kidney or lung, Figure 20C). To verify 
that the recombined allele also resulted in loss of Brg1 protein we analyzed 
expression of Brg1 protein in colon SMCs from Brg1 KO and littermate global 
heterozygous mice using immunohistochemistry. In the control global Brg1 
heterozygous animals (Brg1flox/+:smMHC-cre-/+) there was abundant nuclear 
staining of Brg1 in colon SM cells, while in Brg1 KO mice (Brg1flox/- :smMHC-cre-
/+) little or no Brg1 staining was detected in SMC (Figure 20D).  
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The expression of contractile proteins is not changed in Brg1 KO mice.  We 
utilized immunofluorescent staining of tissue sections, real time RT-PCR analysis 
of mRNA expression and western blotting to evaluate the expression of smooth 
muscle-specific contractile proteins in Brg1 KO mice. Surprisingly, none of these 
approaches revealed any significant changes in the expression of smooth 
muscle-specific contractile proteins such as smooth muscle myosin, smooth 
muscle α-actin, calponin, SM22α, telokin or 130kDa MLCK (Figure 21A, B, C). 
  
The expression of contractile proteins is not changed in Brm null mice. It 
has been reported that Brm null mice are essentially normal except for an 
increase in body and organ size (112). However, no published studies have 
examined SM-specific gene expression in Brm-/- mice. We thus used similar 
approaches to those described above to examine expression of smooth muscle-
specific genes in these mice. From this analysis we did not find any significant 
changes in expression of contractile proteins, in colon and bladder from Brm null 
mice compared with wild type control littermates (Figure 22A, B, C).  In contrast 
to previous reports (112), we also did not observe any compensatory changes in 
expression of Brg1 in the Brm KO mice (Figure 22A, B). 
 
Contractile protein expression is decreased in Brg1/Brm double KO mice.  
As some of our in vitro data suggested that Brg1 and Brm might have redundant 
roles in regulating expression of smooth muscle contractile proteins. Brg1/Brm 
double KO mice (Brg1flox/-:smMHC-Cre-/+: Brm-/-) (smooth muscle-specific Brg1 
 94 
 
KO/global Brg1 het/ global Brm null mice) were generated and analyzed (Figure 
23). Global Brg1 het/Brm null (Brg1flox/-:smMHC-Cre-/-: Brm-/-) mice were used as 
controls for these experiments as these represent mice that only differ from the 
KO animals by the presence of Brg1 in their smooth muscle cells. Decreased 
expression of endogenous contractile proteins, including telokin, 130 kDa MLCK, 
SM22α, calponin, sm α-actin were found by western blotting, and 
immunofluorescence staining of the Brg1/Brm double KO mice as compared to 
the control mice (Figure 24A, B). These results were also confirmed by qRT-PCR 
analysis of mRNA expression (Figure 24C). Although we did not observe any 
decrease in the expression of the SM2 isoform of smMHC by western blot or 
immunofluorescence staining, we did observe a decrease in total smMHC mRNA 
expression.  
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Discussion 
In this study, we found that Brg1 SM-specific knockout and Brm global knockout 
mice had normal SM-specific contractile proteins expression levels, whereas 
Brg1/Brm double knockout mice have attenuated contractile protein expression 
suggesting that Brg1 and Brm have overlapping or redundant functions in 
regulating SM differentiation in vivo.  
 
The findings of the current study are consistent with our in vitro studies in which 
reintroducing either Brg1 or Brm alone restored the myogenic functions of SRF 
cofactors MRTFs in SW13 cells (Figures 7,16). Both these sets of data support 
the hypothesis that Brg1 and Brm have redundant roles in regulating the 
induction of SM contractile proteins. However, these results are not entirely 
consistent with experiments in which we found that depletion of either one of the 
two ATPases, Brg1 or Brm from primary cultures of SMCs, was sufficient to 
decrease SM marker expression (Figure 13). The apparent discrepancy between 
these data could be explained if there is a threshold level of SWI/SNF complexes 
that is required to support smooth muscle differentiation. In vivo it may be 
necessary to delete all four Brg1/Brm alleles in order for SWI/SNF activity to fall 
below this threshold. In contrast, in vitro it may be sufficient to extinguish 
expression of either Brg1 or Brm in order to fall below the critical threshold of 
SWI/SNF activity. Although we can only speculate on the reasons why SMCs 
would require different levels of SWI/SNF activity in vitro and in vivo it is quite 
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possible this reflects differences in the cell’s environment and hormonal mileu or 
differences in the differentiation status of the cells.  
 
The specific functions of Brg1 and Brm and whether these two molecules can 
compensate for each other remains controversial. For example reports have 
shown   Brg1 and Brm to be both pro-proliferative or anti-proliferative. Previous 
studies showed that the proliferation, but not RA-induced differentiation, is 
inhibited in Brg1 heterozygous mutant F9 EC cells (126). The proliferation of 
Brm-/- embryonic fibroblasts is increased as a result of deficiency in cell contact 
induced G0/G1 arrest (112). In contrast, neither Brm nor Brg1 are essential for 
the proliferation and early differentiation of keratinocytes (71). The Reisman 
group has reported that lung specific knockout Brg1 mice had increased cleaved 
caspase-3, a cellular apoptotic marker in lung cells; carcinogen induced  
adenomas in Brg1 null lung tissue had increased proliferation marker Ki67 and 
Proliferating Cell Nuclear Antigen (PCNA). These data suggest that Brg1 and 
Brm have cell specific functions and Brm can compensate for some of Brg1’s 
function in certain types of cells but not others. We will discuss more about the 
redundancy and specificity of these two molecules in next chapter. 
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Figure 20. Generation of smooth muscle-specific Brg1 knockout mice. A. 
Brg1flox/flox: smMHC-Cre-/+ transgenic mice were crossed with Brg1flox/flox: smMHC-
D. 
 
A. 
 
B. 
 
 
C.
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Cre-/- mice to generate SM-specific Brg1 knockout mice (Brg1flox/-: smMHC-Cre-
/+). Global heterozygous Brg1 (Brg1flox/-: smMHC-Cre-/-) mice are used as control. 
B. β-galactosidase activity is smooth muscle-specific in smMHCcre 
ROSA26floxstopfloxLAC mice. C. Smooth muscle-specific recombination of the 
Brg1 locus. Genomic DNA was extracted from tissues of Brg1flox/+: smMHC-Cre-/+ 
(SM specific Brg1 heterozygous). Real time PCR was performing using primers 
that only amplify the recombined Brg1 locus. Levels of the recombined Brg1 
locus were compared to a control single copy gene (telokin) within the same 
sample. Data shown are relative quantity of recombined Brg1 locus after 
normalization to telokin loading control. D. Immunofluorescent analysis of protein 
expression. Anti-Brg1-Fitc (green), MLCK/telokin-Rhodamine (red) and nuclear 
hoechst immunofluorescence staining of colon cryosections from 2-day-old Brg1 
KO (Brg1flox/-:smMHC-Cre-/+) and littermate control (Brg1flox/-:smMHC-Cre-/-) mice.  
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Figure 21. Contractile proteins are not decreased in Brg1 KO mice. A, B. 
Colons from 4-day-old Brg1KO and control mice were dissected and 8 µM 
A 
 
B. 
 
C. 
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cryosections were collected. MLCK/telokin-Rhodamine (red, A), SM2 (smMHC 
isoform2)-FITC (green, B), sm α-actin-FITC (green) and nuclear hoechst 
immunofluorescence staining were performed. The intensity of these SM markers 
in Brg1 KO colon was similar to control colon. C. Left panel, Epithelium layers 
were carefully peeled off colon, ileum and jejune from 3-week-old KO and 
littermate heterozygous control mice. The leftover smooth muscle layers were 
analyzed by western blot. Right panel, proteins extracted from hearts and 
bladders were also examined by western blot. “K”, Brg1KO; “C”, control. 
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Figure 22. Contractile proteins are not decreased in Brm KO mice. A, B. 
Smooth muscle layer were dissected from colons and bladders of 3-week-old 
Brm null and WT control mice. Smooth muscle contractile proteins were 
examined by western blot analysis. There was no significant difference between 
Brm null and WT control mice. C. RNA was extracted from colons and bladders 
of newborn Brm null and control mice. Real time qRT-PCR was performed as 
described in materials and methods. No significant difference was found between 
KO and control samples. 
A. 
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Figure 23. Generating smooth muscle-specific Brg1 KO on Brm null   
background. Male smMHC-Cre+/-Brg1f/wBrm-/- mice were crossed with female 
Brg1 f/f Brm-/- mice to generate Brg1/Brm double knockout (DKO, smMHC-Cre+/-
Brg1f/-Brm-/-, SM-specific Brg1 KO, global Brg1 heterozygous on Brm null 
background). Littermate global Brg1 het/ Brm null mice (smMHC-Cre-/-Brg1flox/-
Brm-/-) were used as controls. 
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Figure 24. Contractile proteins are decreased in Brg1/Brm double KO mice. 
 
C. 
 
B. 
 
A. 
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A. Colon and bladder were dissected from 4-day-old DKO and control mice. 
Contractile proteins 130 kDa MLCK, telokin, calponin, SM22α were decreased in 
western blot analysis. Immunostaining in panel B also confirmed that 
telokin/MLCK (green) expression was down regulated in DKO colon. C. RNA was 
extracted from colon and bladder of newborn DKO mice and littermate control 
mice. qRT-PCR was performed. 
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Chapter V. 
Understanding the GI phenotypes of smooth muscle-specific Brg1 KO and 
Brg1/Brm double KO mice. 
Abstract 
In the last chapter, we have shown the expression of contractile proteins was 
decreased in Brg1/Brm double knockout mice, but not in Brg1 smooth muscle 
specific or Brm global knockout mice. However, these results do not rule out that 
Brg1 or Brm KO mice may have the other smooth muscle related phenotypes. In 
this chapter, we show some interesting phenotypes in these knockout mice. We 
found that the colonic contractility of SM-specific Brg1 knockout mice was 
significantly impaired, probably because of the disorganization of smooth muscle 
cells in the circular SM layer. The colonic contractility was more severely affected 
in Brg1/Brm double KO mice, while it was normal in Brm KO mice. Brg1 KO and 
double KO mice had a shorter gut, which may be caused by decreased 
proliferation in SMCs after knocking out Brg1. This chapter further illustrates the 
important roles of Brg1 and Brm in smooth muscle development and provides 
more evidence that Brg1 can compensate for most, but not all, of the functions of 
Brm in tissue development in vivo. 
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Introduction  
In Chapter IV, we showed that contractile protein expression did not change in 
SM-specific Brg1 KO mice or global Brm KO mice. However, SM-specific Brg1 
KO in a Brm null background mice (double KO) resulted in decreased contractile 
protein expression in smooth muscle tissues. These results suggest that Brg1 
and Brm have overlapping or redundant functions in regulating SM differentiation 
in vivo. The attenuated expression of contractile proteins in the double knockout 
mice also demonstrates that SWI/SNF activity is required for smooth muscle 
differentiation in vivo. It would be predicted that the attenuated contractile protein 
expression observed in the Brg1/Brm double knockout mice would result in 
impaired contractility and function of the GI tract. Brg1/Brm containing SWI/SNF 
chromatin remodeling complexes have also been reported to be involved in 
regulating many cellular functions, such as cell proliferation (126) and apoptosis 
(99) in addition to differentiation. In the current study we have thus examined the 
phenotype of smooth muscle-specific Brg1 KO, Brm KO, and Brg1/Brm double 
KO mice in order to fully characterize the role of SWI/SNF complexes in 
regulating development of the GI tract.  The results of this study revealed that 
although Brg1 and Brm containing SWI/SNF complexes play redundant roles in 
regulating expression of contractile protein genes, Brg1 containing SWI/SNF 
complexes play an additional specific role in GI development perhaps through 
their regulation of smooth muscle cell proliferation. 
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Materials and methods 
 
Contractile measurements of isolated colon rings. Colon was carefully 
dissected and immediately washed in cold PBS.  Surrounding connective tissues 
and fat were gently removed and colon was cut into rings (1 cm axial length). T 
contractility of colon rings was measured as described previously for vascular 
rings (42, 76). Colon rings were mounted on  "L-shaped" stainless steel supports 
and submerged in an 5ml organ bath with Krebs buffer saturated with 95% O2 / 
5% CO2 and held at 37°C. The Krebs buffer contains 132mM NaCl, 25mM 
NaHCO3, 5mM KCl, 2.5mM CaCl2, 1.2mM NaH2PO4, 1.2mM MgCl2, 0.025mM 
EDTA, and 10mM glucose, pH7.4. 2.5g preload was empirically determined to 
result in the optimal length for most the rings tested. To assess smooth muscle 
function colon rings were contracted with 60 mMKCl or 0.1 µM carbachol.  
 
Contractile measurements of isolated whole colon. Colon was removed from 
new born or 4 day old neonatal mice and washed in cold PBS. Colon basal 
spontaneous contractility and contractility stimulated by 60 mM KCl or 0.1 µM 
carbachol were measured using a video microscopy system as described 
previously (84). Briefly, 1 cm lengths of colon was mounted to two canulas which 
were fixed on the edge of an organ bath containing 10 ml 37°C Krebs buffer. One 
canula was connected to pressure regulator through which, 5mmHg pressure 
was applied to the inside of the colon. The diameter changes of the canulated 
colon were observed under a video microscope and quantitated using 
dimensional analysis software (DIAMTRAK 3+, Australia).  
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Immunofluorescence staining. Immunofluorescence staining was performed as 
described in Chapter IV.  
 
Haemotoxylin-eosin staining. Cryosections were air dried in laminar flow hood 
at room temperature for 10 minutes. Then sections were fixed in MeOH: Acetone 
(50:50 dilution) for 30 seconds. Sections were stained in Haemotoxylin for 1 min, 
followed by 3 minutes rinsing in running tap water. Sections were then fixed in 
acid alcohol (70% EtOH/1% HCl) for 1.5-2 minutes. After rinsed in running tap 
water. Sections were stained in Eosin for 2 min. Sections were then destained 
and dehydrated through an ascending series of alcohols (75%, 80%, 90% and 
100% EtOH for 2 minutes each). Finally sections were cleared in Xylene (Fisher) 
1-2 min and cover-slipped using Permount (Fisher). 
 
Electron microscopy: Colons were dissected and fixed in 2% Paraformaldehye-
2% Glutaraldehyde in 0.1M Phosphate Buffer. Then the fixed samples were 
processed for transmission electron microscopy by the IU SOM electron 
microscopy facility (http://www.anatomy.iupui.edu/emcenter/index.html). 70-90nm 
sections were cut and placed on copper grids. Then the cut sections were 
stained with heavy metals, uranyl acetate and lead citrate for contrast. Sections 
were observed on electron microscope Tecnai BioTwin (FEI, Hillsboro, OR). 
Digital pictures were taken using an AMT CCD camera. 
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Smooth muscle cell counting. SM2 (smMHC isoform2) or sm α-actin-Fitc and 
nuclear hoechst immunofluorescence staining were performed on colon 
cryosections from Brg1 KO, DKO and control mice. Nuclei of SM2 or sm α-actin 
positive cells in the circular smooth muscle layer were counted and normalized to 
the area of circular SM layer, which was measured using the Imagetool software. 
 
ECM supperarray. Colon of 3-month-old Brg1 KO and littermate control mice 
was dissected and the epithelium was carefully peeled off. RNA of was extracted 
with Trizol reagent (Invitrogen). Proteinase K and DNase treatments were 
performed to purify RNA. 0.5 µg RNA was used as template to make cDNA using 
RT2 First Strand Kit (SABiosciences). cDNA in RT2 SYBR Green/ROX qPCR 
Master Mix (SA Biosciences) was loaded to 96-well-plate with 84 preloaded ECM 
primers (RT2 Profiler™ PCR Array Mouse Extracellular Matrix and Adhesion 
Molecules, SABioscience, PAMM-013A). 4-fold-difference between Brg1 KO and 
control colon was set as the threshold to determine significant changes. 
 
Quantitative RT-PCR. Quantitative RT-PCR was performed as described in 
Chapter II. 
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Results 
Neonatal lethality in Brg1/Brm double knockout mice. In contrast to either the 
Brg1 or Brm single knockout mice the Brg1/Brm double knockout mice exhibited 
neonatal lethality with no double knockout mice surviving more than 10 days. All 
of the double knockout mice analyzed exhibited intestinal defects such as 
enlarged stomach and/or enlarged small and large intestine (Figure 25E). These 
defects were specific to the double knockout mice as the global heterozygous 
Brg1; Brm null (Brg1flox/-smMHCcre-/-:Brm-/-) mice did not display these 
abnormalities and survived beyond this neonatal period (data not shown). 
Although contractile protein expression in Brg1 KO mice was not significantly 
decreased as compared to control mice, some Brg1 KO mice accumulated gas in 
their intestines and eventually developed mega-colon (Figure 25B). 
 
Colon from Brg1 KO and Brg1/Brm DKO but not Brm KO mice exhibited 
impaired contractility. The pathological phenotypes of Brg1 KO led us to 
measure the contractility of colon from smooth muscle-specific Brg1 KO mice 
(Brg1flox/-smMHC-Cre-/+). Isolated colonic rings from Brg1 KO mice stimulated to 
contract with either 60mM KCl or 0.1µm carbachol exhibited a marked 
impairment of force production as compared to rings obtained from littermate 
control mice (Brg1flox/-smMHC-Cre-/-) (Figure 25A).  
 
Because smooth muscle-specific Brg1/Brm double knockout mice die around day 
7 after birth at which time their colon is very small we were not able to measure 
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the contractility of colonic rings in the same manner as described above for the 
Brg1 KO mice. As an alternative approach we measured the contractility of 
canulated colonic segments using videomicroscopy. This analysis revealed that 
the normal basal spontaneous contractile activity of control colon (mainly in the 
proximal end) was completely absent in colon from Brg1/Brm double KO mice. 
To further quantitate these changes, the diameter of the colons from control 
(Brg1flox/-Brm-/-smMHC-Cre-/-) and double KO (Brg1flox/-Brm-/-smMHC-Cre+/-) mice 
were recorded over time and a representative plot is shown in Figure 25C.  The 
increases and decreases of diameter of the colon correlate to the relaxation and 
contraction of circular SM layer, respectively. In colon from control mice, 
diameters spontaneously changed from 2100 µm to 1800 µm, while the diameter 
of colon from double KO mice remained constant at 2400 µm (Figure 25C). The 
larger resting diameter of the colon from double KO (2400 µm as compared to 
2100 µm) is indicative of a dilated colon. The lack of in vitro motility within the 
colon is consistent with the in vivo phenotype of the double KO mice which all die 
4 to 7 days after birth exhibiting dilated colon, stomach, small intestine and 
bladder (Figure 25D), indicative of impaired GI motility.  Using the same method, 
we observed no differences in the contractility of colon from Brm KO mice as 
compared to colons from littermate Brm heterozygous and wild type control mice 
(data not show). 
 
SMCs in the colon of Brg1 KO and Brg1/Brm double KO mice have altered 
alignment. Smooth muscle myosin heavy chain SM2 immunofluorescent 
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staining, and HE staining of colon from new born and 3-month-old Brg1 KO 
(Brg1flox/-smMHC-Cre-/+) and littermate control (Brg1flox/-smMHC-Cre-/-) revealed a 
disorganization of the circular smooth muscle layer.  The smooth muscle cells 
within the circular smooth muscle layer of the colon in Brg1 KO mice were not 
aligned as evenly as those of control mice  (Figures 21A, B; 26A, B). The SMCs 
in KO colon appear to have lost the typical spindle shape of normal SMCs 
(Figure 21A,B; 26A,B). Similarly, the SMCs in the circular smooth muscle layer of 
colon from Brg1/Brm double KO mice were also disorganized (Figures 24B, 
26E), whereas SMC in the colon of Brm KO mice appeared normal (Figure 26D).  
The disorganization of the smooth muscle layer observed in Brg1 KO and double 
KO mice maybe one of the causes of the decreased contractility of the colonic 
tissue. 
 
 To more closely examine the details of this SMC disorganization, we used 
electron microscopy. This analysis revealed that there was more space between 
circular SMCs in colon from Brg1 KO mice (Figure 26C). Furthermore, the 
borders of the circular smooth muscle cells were much more ruffled (or 
invaginated) in colon from KO mice as compared to controls (Figure 26C). 
 
ECM proteins are not changed in Brg1 KO or DKO SM tissues. Since our 
initial analysis revealed that the shape of smooth muscle cells from Brg1 KO 
mice is altered we examined the possibility that the cells have aberrant 
expression of extracellular matrix (ECM) and adhesion molecules. For this 
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analysis an ECM qRT-PCR array was screened (Superarray, SABiosciences) 
using RNA extracted from colon of 3-week-old Brg1 KO and littermate control 
mice. Results showed that several genes were up-regulated (Adamts1, Emilin1, 
Icam1), while Sparc was down regulated (Figure 27A). However, we were not 
able to confirm these changes using qRT-PCR of multiple independent samples 
(Figure 27B). In this latter analysis we also examined genes which have been 
previously shown to be Brg1 target genes in other cell types, Bmp4, Col1a1, 
Col4a1, Col5a1, Gli1, Gli2, Itgam (48) (77), but no significant changes in 
expression of these genes were observed in colon from Brg1 KO mice (Figure 
27C). 
 
Gut is shorter in Brg1 KO and DKO mice. Although we did not observe any 
changes in the density of SMC in sections from the colon of Brg1 KO mice both 
the colon and small intestine were significantly shorter in these mice (Figure 
28A). Body weight, body length (from nose to anus) and tibial length were also 
measured but not found to be any different between Brg1 KO, Brm KO, Brg1/Brm 
double KO and littermate control mice (Figure 28 B and data not shown). When 
colon and small intestine length were normalized to body weight, body length or 
tibial length, results showed that Brg1 KO and Brg1/Brm double KO colon and 
small intestine were significantly shorter than littermate controls (Figure 28B,D). 
However, neither colon nor small intestine length was changed in Brm KO mice 
compared with WT or heterozygous littermate controls (Figure 28B).  
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Shorter gut in Brg1 KO and DKO is probably caused by decreased 
proliferation but not by increased apoptosis. It has been reported that Brg1 
regulates cell apoptosis and proliferation (99, 126, 136). We hypothesized that 
knocking out Brg1 in SMCs could increases apoptosis and/or decrease 
proliferation of SMCs resulting in a shorter gut. To evaluate apoptosis we 
performed immunofluorescent staining of cleaved caspase-3 on sections of colon 
obtained from newborn and 3-month-old Brg1 mice (Figure 29A) or colon from 
E19.5 and newborn Brg1/Brm double KO mice (Figure 29B). Although the 
epithelium layer had several cleaved caspase-3 positive cells in colon from both 
3-month-old Brg1 KO and control mice, as expected (68), SMCs had no or rare 
cleaved caspase-3 positive staining in sections from all the groups of mice we 
examined with no differences detectable between Brg1 KO, Brg1/Brm double KO 
and control mice (Figure 29A, B). Similarly, phospho-H2AX staining was rarely 
detectable in SMC and not significantly different in colonic sections from Brg1 
KO, Brg1/Brm double KO and control mice (data not shown). 
 
 To examine possible changes in SMC proliferation we performed 
immunofluorescent staining for Ki67. Ki67 is a commonly used cellular marker for 
proliferation (103). In the colon from 3-month-old Brg1 KO and control mice, Ki67 
positive cells were found in the crypt epithelium above the submucosa layer, but 
not in SMCs as reported previously (103) (Figure 30A). However, in the colon 
from Brg1/Brm double KO mice at E19.5 and new born, Ki67 positive staining 
were found in both epithelium and SM layer (Figure 30B). Interestingly, we found 
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there were significant less Ki67 positive SMCs in the colonic circular SM layer 
from newborn double KO mice compared to littermate control mice, while current 
data showed there was no difference in E19.5 mice (Figure 30B, C). This is 
suggesting that the slower proliferation of colonic circular SMCs from DKO mice 
starts after birth, which is consistent with the observed decrease in colon length 
from after born DKO mice, but not apparent in embryonic DKO mice(data now 
shown).  A similar analysis is currently in progress in tissues from Brg1 single KO 
mice. Furthermore, we will also investigate other markers of proliferation such as 
PCNA and a BrDU labeling assay to confirm these results.  
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Discussion 
In this study, we found that both smooth muscle-specific Brg1 knockout mice and 
smooth muscle-specific Brg1 knockout mice on a Brm null background exhibit 
impaired GI contractility. This phenotype is more severe in the double knockout 
mice that exhibit neonatal lethality. This is consistent with the attenuated 
contractile protein expression seen in the GI tract of double but not single 
knockout mice. Together our data suggest that Brg1 and Brm-containing 
SWI/SNF complexes play redundant roles in regulating expression of smooth 
muscle contractile proteins during GI development. Whereas the pathological 
phenotype of the smooth muscle-specific Brg1 KO mice in the presence of 
normal levels of Brm suggests Brg1-containing SWI/SNF complexes play 
additional roles in GI development that cannot be performed by Brm-containing 
SWI/SNF complexes.  
 
As SMCs are disorganized in the colon of Brg1 KO and Brg1/Brm double KO 
mice, but not Brm KO mice, this would suggest that this disorganization is a 
result of the specific loss of Brg1-containing SWI/SNF complexes. We have thus 
far been unable to identify the specific Brg1 target genes that result in this 
phenotype. Our initial results have ruled out a number of ECM and signaling 
proteins such as BMP4, Gli1, and Gli2. To better identify the Brg1-specific target 
genes we will need to perform a whole genome wide array analysis of smooth 
muscle cells isolated from Brg1 KO mice.   
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 Our data showing a decreased intestinal length in smooth muscle-specific Brg1 
knockout and Brg1/Brm double knockout but not Brm knockout mice suggest that 
this phenotype is likely a specific consequence of the loss of Brg1-containing 
SWI/SNF complexes. The decreased rate of SMC proliferation, in the absence of 
any changes in apoptosis, observed in the Brg1/Brm double KO mice could 
account for the shorter intestines in these mice. A similar analysis in the Brg1 KO 
mice is in progress to confirm that the defect in proliferation is a specific 
consequence of loss of Brg1. Loss of Brg1 could affect SMC proliferation in a 
number of ways. it has been reported that  Brg1 affected cell cycle by regulating 
the expression of Cyclin A, E and p21 (59, 74). Also, Brg1 over expression in 
mesenchymal stem cells (MSCs) induced programmed cell death triggered by 
activated p53 pathway; however, this Brg1 induced apoptosis cannot be 
prevented by the anti-apoptotic regulator Rb.  
 
Brg1 could also affect proliferation more indirectly through changes in nuclear 
structure. The loss of Brg1 may act to change gene expression through changing 
heterochromatin structure. Bourgo et al reported (13) that deletion of Brg1 in 
primary murine adult fibroblasts (MAFs) caused nuclear malformation. The 
normally discrete pericentometric heterochromatin domains were disorganized 
and dispersed; correspondingly, heterochromatin related modifications such as 
histone H3-trimethyl lysine 9 and H4-trimethyl lysine 20 were also dispersed, 
whereas the euchromatin related acetylation of histone H4 and histone H3 were 
unaffected. Interestingly, this heterochromatin disorganization was specific for 
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Brg1 depletion; Brm or SNF5 depletion had no such defects. Furthermore, Brg1 
depleted MAFs also had remarkably increased micronuclei, while Brm deficient 
MAFs only had modestly increased micronuclei. Together these data suggest 
that Brg1, but not Brm, is the main factor that regulating heterochromatin 
organization. Chromatin disorganization can affect cell proliferation and genome 
stability (72) (83, 85), Consistently, Brg1 deficient MAFs showed decreased 
proliferation, which is likely due to aberrant mitotic cell division caused by 
disrupted chromatin structure. Further studies will be required to resolve which of 
these mechanisms result in the altered proliferation of GI smooth muscle cells. 
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Figure 25. The contractility of the colon from Brg1 knockout mice is 
remarkably impaired. A. Left panel. Rings of colonic tissue were hung in a 
myograph and contractility measured in response to KCl induced membrane 
depolarization or the muscurinic agonist carbachol. The contractility of the colon 
from knockout mice is impaired. B. Some Brg1 KO mice developed megacolon in 
A. 
 
B.  
 
C. 
 
E.      DKO                       Cont   
 
D.  
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proximal end and enlarged ileum. C, D. The contractility of colon was impaired in 
Brg1/Brm DKO mice. “C” is a video, showing that the spontaneous contraction of 
proximal end of colon from new born DKO mice was decreased; “D” is recording 
the spontaneous diameter changes in the video “C” and after stimulation by 
0.1µm carbachol. E. Stomach, intestine and bladder were dilated in DKO mice. 
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Figure 26. SMCs in the colon of Brg1 KO and Brg1/Brm double KO mice 
have altered alignment. A. SM2 immunofluorescent staining (red) and Hoechst 
nuclear staining (blue) of colon from 3-month-old Brg1 KO mice. B. HE staining 
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C. 
 
E. 
 
D. 
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of colon from 3-month-old Brg1 KO mice. C. Ultra-structure of colon from 3-
month-old Brg1 KO mice and littermate control using Electron Microscopy. D. 
MLCK immunofluorescent staining (red) and hoechst nuclear staining (blue) of 
colon from newborn Brm KO mice and WT littermates. E. sm α-actin 
immunofluorescent staining (red) and Hoechst nuclear staining (blue) of colon 
from E19.5 DKO mice. 
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Figure 27. ECM proteins are not changed in Brg1 KO or DKO SM tissues. A. 
Supperarray results showed some extracellular matrix proteins increased in Brg1 
KO colon (Adamts1, Emilin1, Icam1), while Sparc decreased. B. Quantitative RT-
PCR results showed no changes of Adamts1, Emilin1, Icam1, Sparc in colon and 
bladder from Brg1 KO by using customized primers and didn’t confirm the 
Supperarray results in “A”. C. Quantitative RT-PCR results showed no changes 
of possible Brg1 target genes Bmp4, Col1a1, Col4a1, Col5a1, Igf1, Igf2, Gli1, 
Gli2 and Itgam, in the colon and bladder from Brg1 KO mice.  
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Figure 28. The gut of Brg1 KO and DKO mice is shorter than heterozygous 
B. 
 
D. 
 
C. 
 
A. 
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littermates. A. The density of SMCs in colonic circular layers from Brg1 KO and 
DKO mice was not decreased. B. The colon and small intestine (SI) of Brg1 KO 
mice were significantly shorter (about 20%) than the global heterozygous 
littermates after normalized to body length, tibial length or body weight. Body 
length, tibial length, or body weight of Brg1KO mice are not significantly different 
from littermate heterozygous controls. C. Gut length after normalizing to body 
length, tibial length or body weight, was not changed in Brm KO mice as 
compare to littermate WT or Brm heterozygous control mice. D. Colon and small 
intestine (SI) were shorter in DKO mice. 
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Figure 29. Activated caspase 3 expression is not increased in Brg1 KO or 
DKO colon. A. Cleaved caspase 3 immunofluorescent staining (red in left panel, 
green in right panel) and Hoechst nuclear staining (blue) in colon from new born 
(left panel) and 3-month-old Brg1 KO mice (right panel).  Arrows are pointing to 
 
B.
 
 
A. 
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cleaved caspase 3 positive SMCs. B. Cleaved caspase 3 immunofluorescent 
staining (green), sm α-actin (red) and Hoechst nuclear staining (blue) in colon 
from E19.5 (upper panel) and newborn DKO mice (lower panel). 
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Figure 30. Ki 67 positive cells are decreased in the colon from new born 
DKO mice.  A. Ki67 immunohistochemistry staining (brown) of colon from 3-
month-old Brg1 KO mice. B. Ki67 immunofluorescent staining (green), 
telokin/MLCK (red) and Hoechst nuclear staining (blue) in colon from E19.5 
(upper panel) and newborn DKO mice (lower panel). C. The percentage of Ki67 
A. 
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positive SMCs in the circular muscle layer of colon from E19.5 (upper panel) and 
newborn DKO mice (lower panel). 
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Table 1: 
Primers used for quantitative RT-PCR primers 
SM α-actin  F: 5’-CCA GAG TGG AGA AGC CCA GC-3’ 
 R: 5’-GGC TGT GCT GTC TTC CTC TTC AC-3’ 
Brg1 F: 5’-CCA TCC TGG AGC ACG AGG AGC-3’  
 R: 5’-GGT CCA TGC GCA TGA ACA GAT C-3’ 
C-fos   Qiagen QuantiTect Primers  
Calponin F: 5'-CCAGCCAGGCTGGCATGACTGC-3' 
 R: 5'-CCTTGTTGCTGCCCATCTGC-3' 
Egr1 F: 5’-GAG CAC CTG ACC ACA GAG TC-3’ 
 R: 5’-CCA CAA AGT GTT GCC ACT GTT G-3’ 
Hprt F: 5’-TGGCCCTCTGTGTGCTCAA-3’ 
 R: 5’-TGATCATTACAGTAGCTCTTCAGTCTGA 
MRTFA F: 5'-GCATTTCATGAGCAGAGAAGAAGCC-3' 
 R: 5'-CTACCTTTGGGTAATTTACCTGGCC-3' 
Myocardin F: 5'-CAGCTACCCTGGGATGCACCAAACAC -3' 
 R: 5'-GGGGCCTGGTTTGAGAGAAGAAACACC -3' 
RPLPO 
(36B4) F: 5’-GGA CCC GAG AAG ACC TCC TT-3’  
 R: 5’-TGC TGC CGT TGT CAA ACA CC-3’ 
SM22α F: 5’-CGA AGC CAG TGA AGG TGC CTG AGA AC-3’ 
 R: 5’-CCC AAA GCC ATT AGA GTC CTC TGC AC-3’ 
SRF F: 5’-GTT CAT CGA CAA CAA GCT GC-3’  
 R: 5’-CTG TCA GCG TGG ACA GCT CAT AG-3’ 
Telokin F: 5’-GAC ACC GCC TGA GTC CAA CCT CCG-3’  
 R: 5’-GGC TTT TCC TCA GCA ACA GCC TCC-3’ 
Vinculin  Qiagen QuantiTect Primers 
Adamts1 F: 5’-CTG GGC AAG AAA TCT GAT GA-3’ 
 R: 5’-AAG CAC AGC CAC AGT TTA TCA-3’ 
Emilin1 F: 5’- TGT GCC TAG GGT AGC ATT TTC-3’ 
 R: 5’- GAG GCT GAA GAC GCC CAG AG-3’ 
Icam1 F: 5’- GTG GTG AAG TCT GTC AAA CAG GAG-3’ 
 R: 5’- ATT CCT GGT GAC ATT CCC ATG-3’ 
Sparc F: 5’- TGA GAA TGA GAA GCG CCT GGA-3’ 
 R: 5’- AAG GGG GTA ATG GGA GGG GTG-3’ 
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Table2: 
Primers used in ChIP Assays 
SM  α-actin F: 5'AGCAGAACAGAGGAATGCAGTGGAA3' 
 R: 5'CCTCCCACTCGCCTCCCAAACAAGGA3' 
c-fos F: 5'CGGTTCCCCCCCTGCGCTGCACCCTC3' 
 R: 5'AGAACAACAGGGACCGGCCGTGGAAA3' 
SM22α F: 5'GACCCCCGCAGCATCTC3' 
 R: 5'GACACCAAGTTGGAGCAGTCTGT3' 
SRF F: 5'TGACAGCAGCGAGTTCGGTAT3' 
 R: 5'GGCACCTAGGCTCCCCATTT3' 
Telokin F: 5'GGGCCCAGTCAGCAATAAGTC3' 
 R: 5'CTGTGCTTCAACTCCCATAAAAGG3' 
 
Note: the ChIP primer sequences for SM α-actin and c-fos are from McDonald et 
al, J. Clinical Investigation, 2006.  
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Table 3: 
Primers used for mouse genotyping 
 
Amplicon 
(bp) 
Brg1 Flox TG57: GCCTTGTCTCAAACTGATAAG 387 
 TH185: GTCATACTTATGTCATAGCC  
Brg1 WT TG57: GCCTTGTCTCAAACTGATAAG 241 
 TH185: GTCATACTTATGTCATAGCC  
Brm WT F: CCTGAGTCATTTGCTATAGCCTGTG 700 
 R1: CTGGACTGCCAGCTGCAGAG  
Brm KO F: CCTGAGTCATTTGCTATAGCCTGTG 310 
 R2: CATCGCCTTCTATCGCCTTC  
Cre F: CATTTGGGCCAGCTAAACAT 450 
 R: CCCGGCAAAACAGGTGTTA  
ROSA26R Rs1: AAAGTCGCTCTGAGTTGTTAT 275 
 Rs2: GCGAAGAGTTTGTCCTCAACC  
ROSA WT Rs1: AAAGTCGCTCTGAGTTGTTAT 600 
 Rs3: GGAGCGGGAGAAATGGATATG  
 
Notes:  
1. The primers sequences for Brg1 and Brm are from Bultman, et al, Mol 
Cell, 2000. 
2. ROSA26R and cre primers are obtained from Conway lab in Indiana 
University. 
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Discussion and Future Directions 
In my thesis project, I have studied the roles of Brg1 and Brm in regulating 
smooth muscle differentiation and development in vitro and in vivo. Furthermore, 
the overlapping and non-overlapping functions of Brg1 and Brm were 
investigated. I have shown that (1) Brg1/Brm are required for the induction of 
SM-specific genes by MRTFs and Brg1/Brm containing SWI/SNF chromatin 
remodeling complexes have overlapping functions in supporting the myogenic 
activity of the MRTFs in non-muscle cells. However, Brg1 and Brm may play non-
overlapping roles in maintaining high expression levels of smooth muscle-specific 
genes in differentiated SMCs. Brg1 and Brm regulated expression of contractile 
protein genes through regulating SRF and MRTF binding. (2) Brg1 and Brm play 
redundant role in regulating smooth muscle contractile proteins expression in 
vivo. Both Brg1 and Brm single KO mice had normal smooth muscle contractile 
proteins expression levels. However, Brg1/Brm double KO mice had significant 
decreased expression of smooth muscle contractile proteins. (3) Brg1, not Brm, 
has indispensible roles in regulating the length of GI tract and smooth muscle cell 
morphology, GI contractility and nutrition absorption. Interestingly, Brg1/Brm 
double KO mice have more severe gut defects than Brg1 single KO mice, 
although Brm single KO mice have no obvious gut defects. This suggests that 
Brg1 can compensate for most functions of Brm in regulating gut proliferation and 
differentiation, but that Brm cannot fully compensate for the lack of Brg1. These 
specific functions of Brg1 are still an unsolved puzzle, as we have not yet 
identified the specific Brg1 target genes or pathways that they regulate.  To begin 
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to address this issue we explored the possible mechanisms that could result in 
the shorter intestines seen in Brg1 single and Brg1/Brm double KO mice. These 
preliminary analyses suggest that Brg1 may affect the proliferation, but not 
apoptosis of developing SMCs.  
 
We observed a disorganization of SMCs in the circular layer of colons from Brg1 
single and Brg1/Brm double KO mice. We initially postulated that this might 
reflect a change in the expression of cell-cell or cell-matrix adhesion molecules. 
However, examination of expression of genes encoding 84 different ECM 
proteins failed to show any significant changes in expression of these genes 
(Figure 27). Future experiments will use a more comprehensive whole genome 
wide array analysis in order to identify the genes whose expression is changed 
by specific deletion of Brg1 from smooth muscle cells.  
 
Brg1 single and Brg1/Brm double KO mice develop gut defects including shorter 
gut, decreased contractility and megacolon. These defects mimic those seen in 
some human GI tract diseases, such as short gut syndrome, intestinal pseudo-
obstruction and idiopathic megacolon. The molecular mechanisms resulting in 
these diseases, especially the role of chromatin remodeling, are largely 
unknown. It is widely appreciated that chromatin epigenetic regulation plays an 
important role in human diseases, including cardiovascular and skeletal muscle 
related diseases (55) (90, 96). Based on my thesis findings it is thus tempting to 
speculate that changes in the expression of Brg1 may contribute to the pathology 
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of human GI tract diseases. Future studies will be aimed at examining the 
expression of Brg1 and Brm in animal intestinal disease models, such as chronic 
partial obstruction of small intestine (29).  
 
In the introduction, I discussed the close and complex cross-talk between 
epithelial and smooth muscle layers during GI tract development that involves 
many signaling pathways. Consequently although we knocked out Brg1 only in 
smooth muscle cells, it is reasonable to hypothesize that the aberrant smooth 
muscle in Brg1 single and Brg1/Brm double KO mice may affect the 
differentiation, morphology or functions of the epithelial cells. In terms of gross 
morphology, based on H&E staining result (in Figure 26B) we did not observe 
any dramatic changes in the colonic epithelium from Brg1, Brm or Brg1/Brm 
knockout mice. However, the phenotype of the epithelial cells needs to be 
examined more specifically to rule out possible changes in differentiation of 
epithelium in these KO mice.  
 
Smooth muscle containing organs include not only the GI tract but also many 
other organs including the urinary tract, reproductive tract and vasculature 
system. In my in vitro studies, I observed similar roles for Brg1 and Brm in SMCs 
isolated from colon, bladder and aorta. However, in my in vivo studies, I have 
currently focused only on defects in the gut, largely because GI defects are the 
most obvious phenotypes observed in the KO mice. However, since there are 
many similarities in the differentiation of GI, urinary, reproductive and vascular 
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SMCs, it is quite possible that these other organ systems may also exhibit 
defects in our KO mice. In the future, we will particularly focus on extending our 
studies to the urinary and vasculature system of these KO mice. In the Brg1/Brm 
double KO mice we have observed enlarged bladders suggesting that the 
smooth muscle in this urinary organ may be similarly affected to the GI smooth 
muscle. Currently, we have not observed obvious bleeding or heart defects 
reflecting the defects of the vascular development in embryo or adult stages of 
Brg1, Brm or double KO mice.  However, further studies will be required to more 
carefully assess the function of the vasculature in the KO mice. In addition, it is 
possible that the pathological remodeling that occurs in vascular diseases or 
following vascular injury may be altered in the KO mice. As discussed in the 
introduction, in vascular diseases such as atherosclerosis, hypertension or 
animal vascular injury models, the affected SMCs are undergoing dramatic 
phenotypic changes (104) (144) from contractile to synthetic phenotypes and 
back; correspondingly, the expression levels of contractile proteins are also 
dynamically changing. In my thesis study, I have showed that Brg1 and Brm play 
important roles in regulating colon SMC genes expression, proliferation and 
phenotype changes. It is thus very likely that Brg1 and/or Brm may be involved in 
the pathology process of vascular diseases. To test this hypothesis I would 
propose to perform a carotid artery injury (144) in Brg1 or Brm single KO mice 
and examine the subsequent remodeling of the carotid artery in these mice as 
compared to control mice.  
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In summary, studies described in my thesis are the first to demonstrate a role of 
Brg1/Brm containing SWI/SNF chromatin remodeling complexes in regulating 
smooth muscle differentiation and development. Our unique SM cell-specific 
Brg1 knockout mouse may also provide a new disease model to study intestinal 
smooth muscle related diseases and thus contribute to a better understanding of 
these diseases that will aid in developing better therapeutic strategies. 
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